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1. Preamble
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in
proposing the best management strategies for an individual patient with a given condition. Guidelines and
their recommendations should facilitate decision making of health professionals in their daily practice.
However, the final decisions concerning an individual patient must be made by the responsible health
professional(s) in consultation with the patient and caregiver as appropriate.
A great number of guidelines have been issued in recent years by the European Society of Cardiology
(ESC), as well as by other societies and organisations. Because of their impact on clinical practice, quality
criteria for the development of guidelines have been established in order to make all decisions transparent
to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC
website (www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Guidelines-development/
Writing-ESC-Guidelines). The ESC Guidelines represent the official position of the ESC on a given topic
and are regularly updated.
Author/Task Force Member Affiliations, ESC Committee for Practice Guidelines (CPG) members and National Cardiac
Societies document reviewers are listed in the Appendix.
M. Humbert, M. Delcroix, S. Gaine, O. Sanchez and A. Vonk Noordegraaf are Task Force Members representing the ERS.
ESC entities having participated in the development of this document are as follows. Associations: Acute Cardiovascular
Care Association (ACCA), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of
Cardiovascular Imaging (EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), Heart
Failure Association (HFA). Councils: Council on Cardiovascular Primary Care. Working Groups: Aorta and Peripheral
Vascular Diseases, Cardiovascular Surgery, Pulmonary Circulation and Right Ventricular Function, Thrombosis
This publication is for personal and educational use only. No commercial use is authorized. No part of the ESC
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be
obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal
and the party authorized to handle such permissions on behalf of the ESC ( journals.permissions@oxfordjournals.org).
Disclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the
scientific and medical knowledge, and the evidence available at the time of their publication. The ESC is not responsible
in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other official
recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of
healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account
when exercising their clinical judgment, as well as in the determination and the implementation of preventive,
diagnostic, or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the
individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s
caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the
relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to
manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional
obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to
drugs and medical devices at the time of prescription.
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BOX 1 Abbreviations and acronyms
AcT Right ventricular outflow Doppler acceleration time
AFE Amniotic fluid embolism
ALT Alanine aminotransferase
AMPLIFY Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein
Thrombosis as First-line Therapy
ASPIRE Aspirin to Prevent Recurrent Venous Thromboembolism trial
AV Arteriovenous
b.i.d. Bis in die (twice a day)
BNP B-type natriuretic peptide
BP Blood pressure
BPA Balloon pulmonary angioplasty
b.p.m. Beats per minute
CI Confidence interval
CO Cardiac output
CPET Cardiopulmonary exercise testing
CPG Committee for Practice Guidelines
CrCl Creatinine clearance
CRNM Clinically relevant non-major (bleeding)
CT Computed tomogram/tomographic/tomography
CTED Chronic thromboembolic disease
CTEPH Chronic thromboembolic pulmonary hypertension
CTPA Computed tomography pulmonary angiography/angiogram
CUS Compression ultrasonography
CYP3A4 Cytochrome 3A4
DAMOVES D-dimer, Age, Mutation, Obesity, Varicose veins, Eight [coagulation factor VIII], Sex
DASH D-dimer, Age, Sex, Hormonal therapy
DVT Deep vein thrombosis
ECMO Extracorporeal membrane oxygenation
ELISA Enzyme-linked immunosorbent assay
EMA European Medicines Agency
ERS European Respiratory Society
ESC European Society of Cardiology
FAST H-FABP, Syncope, Tachycardia (prognostic score)
FDA US Food and Drug Administration
GUSTO Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded
Coronary Arteries
HAS-BLED Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition,
Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly
HERDOO2 Hyperpigmentation, Edema, or Redness in either leg; D-dimer level ⩾250 μg/L; Obesity
with body mass index ⩾30 kg/m2; or Older age, ⩾65 years
H-FABP Heart-type fatty acid-binding protein
HIV Human immunodeficiency virus
HR Hazard ratio
INR International normalized ratio
IU International units
i.v. Intravenous
IVC Inferior vena cava
LA Left atrium
LMWH Low-molecular weight heparin(s)
LV Left ventricle/ventricular
MRA Magnetic resonance angiography
NCT National clinical trial
NOAC(s) Non-vitamin K antagonist oral anticoagulant(s)
NT-proBNP N-terminal pro B-type natriuretic peptide
NYHA New York Heart Association
OBRI Outpatient Bleeding Risk Index
o.d. Omni die (once a day)
OR Odds ratio
PAH Pulmonary arterial hypertension
PAP Pulmonary artery pressure
PE Pulmonary embolism
PEA Pulmonary endarterectomy
PEITHO Pulmonary Embolism Thrombolysis trial
PERC Pulmonary Embolism Rule-out Criteria
PERT Pulmonary Embolism Response Team
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The ESC carries out a number of registries which are essential to assess, diagnostic/therapeutic processes,
use of resources and adherence to Guidelines. These registries aim at providing a better understanding of
medical practice in Europe and around the world, based on data collected during routine clinical practice.
The guidelines are developed together with derivative educational material addressing the cultural and
professional needs for cardiologists and allied professionals. Collecting high-quality observational data, at
appropriate time interval following the release of ESC Guidelines, will help evaluate the level of
implementation of the Guidelines, checking in priority the key end points defined with the ESC
Guidelines and Education Committees and Task Force members in charge.
The Members of this Task Force were selected by the ESC, including representation from its relevant ESC
sub-specialty groups, in order to represent professionals involved with the medical care of patients
with this pathology. Selected experts in the field undertook a comprehensive review of the published
evidence for management of a given condition according to ESC Committee for Practice Guidelines
(CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including
assessment of the risk–benefit ratio. The level of evidence and the strength of the recommendation of
particular management options were weighed and graded according to predefined scales, as outlined in
tables 1 and 2.
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships
that might be perceived as real or potential sources of conflicts of interest. These forms were compiled
into one file and can be found on the ESC website (www.escardio.org/guidelines). Any changes in
declarations of interest that arise during the writing period were notified to the ESC and updated. The
Task Force received its entire financial support from the ESC without any involvement from the healthcare
industry.
The ESC CPG supervises and coordinates the preparation of new Guidelines. The Committee is also
responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive
review by the CPG and external experts. After appropriate revisions the Guidelines are approved by all the
experts involved in the Task Force. The finalized document is approved by the CPG for publication in the
European Heart Journal. The Guidelines were developed after careful consideration of the scientific and
medical knowledge and the evidence available at the time of their dating.
The task of developing ESC Guidelines also includes the creation of educational tools and implementation
programmes for the recommendations including condensed pocket guideline versions, summary slides,
PESI Pulmonary Embolism Severity Index
P-gp P-glycoprotein
PH Pulmonary hypertension
PIOPED Prospective Investigation On Pulmonary Embolism Diagnosis
PISAPED Prospective Investigative Study of Acute Pulmonary Embolism Diagnosis
PREPIC Prevention of Recurrent Pulmonary Embolism by Vena Cava Interruption
PVR Pulmonary vascular resistance
RA Right atrium/atrial
RCT Randomized controlled trial
RIETE Registro Informatizado de la Enfermedad Thromboembolica venosa
RR Relative risk
rtPA Recombinant tissue-type plasminogen activator
RV Right ventricle/ventricular
SaO2 Arterial oxygen saturation
SPECT Single-photon emission computed tomography
sPESI Simplified Pulmonary Embolism Severity Index
SURVET Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis study






VKA(s) Vitamin K antagonist(s)
V/Q Ventilation/perfusion (lung scintigraphy)
VTE Venous thromboembolism
VTE-BLEED ActiVe cancer, male with uncontrolled hyperTension at baseline, anaEmia, history of
BLeeding, agE ⩾60 years, rEnal Dysfunction
WARFASA Warfarin and Aspirin study
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booklets with essential messages, summary cards for non-specialists and an electronic version for digital
applications (smartphones, etc.). These versions are abridged and thus, for more detailed information, the
user should always access to the full text version of the Guidelines, which is freely available via the ESC
website and hosted on the EHJ website. The National Societies of the ESC are encouraged to endorse,
translate and implement all ESC Guidelines. Implementation programmes are needed because it has been
shown that the outcome of disease may be favourably influenced by the thorough application of clinical
recommendations.
Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their
clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or
therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the
individual responsibility of health professionals to make appropriate and accurate decisions in
consideration of each patient’s health condition and in consultation with that patient or the patient’s
caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the
rules and regulations applicable in each country to drugs and devices at the time of prescription.
2. Introduction
2.1. Why do we need new Guidelines on the diagnosis and management of pulmonary embolism?
This document follows the previous ESC Guidelines focusing on the clinical management of pulmonary
embolism (PE), published in 2000, 2008, and 2014. Many recommendations have been retained or their
validity has been reinforced; however, new data have extended or modified our knowledge in respect of the
optimal diagnosis, assessment, and treatment of patients with PE. These new aspects have been integrated
into previous knowledge to suggest optimal and—whenever possible—objectively validated management
strategies for patients with suspected or confirmed PE. To limit the length of the article text, additional
information, tables, figures, and references are available as supplementary data.
These Guidelines focus on the diagnosis and management of acute PE in adult patients. For further details
specifically related to the diagnosis and management of deep vein thrombosis (DVT), the reader is
referred to the joint consensus document of the ESC Working Groups of Aorta and Peripheral Vascular
Diseases, and Pulmonary Circulation and Right Ventricular Function [1].
TABLE 2 Levels of evidence
Level of
evidence A
Data derived from multiple randomized clinical traits or meta-analyses
Level of
evidence B
Data derived from a single randomized clinical trial or large non-randomized studies
Level of
evidence C
Consensus of opinion of the experts and/or small studies, retrospective studies, registries
TABLE 1 Classes of recommendations
Recommendation Definition
Class I Evidence and/or general agreement that a 
given treatment or procedure is beneficial, 
useful, effective.
Wording to use
Is recommended or is indicated
Class II Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of
the given treatment or procedure





Usefulness/efficacy is less well 
established by evidence/opinion.
May be considered
Evidence or general agreement that the 
given treatment or procedure is not 
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2.2. What is new in the 2019 Guidelines?
2.2.1. New/revised concepts in 2019
Diagnosis
D-dimer cut-off values adjusted for age or clinical probability can be used as an alternative to the fixed
cut-off value.
Updated information is provided on the radiation dosage when using CTPA and a lung scan to diagnose PE (table 6).
Risk assessment
A clear definition of haemodynamic instability and high-risk PE is provided (table 4).
Assessment of PE severity and early PE-related risk is recommended, in addition to comorbidity/
aggravating conditions and overall death risk.
A clear word of caution that RV dysfunction may be present, and affect early outcomes, in patients at “low
risk” based on clinical risk scores.
Treatment in the acute phase
Thoroughly revised section on haemodynamic and respiratory support for high-risk PE (Section 6.1).
A dedicated management algorithm is proposed for high-risk PE (supplementary figure 1).
NOACs are recommended as the first choice for anticoagulation treatment in a patient eligible for NOACs;
VKAs are an alternative to NOACs.
The risk-adjusted management algorithm (figure 6) was revised to take into consideration clinical PE
severity, aggravating conditions/comorbidity, and the presence of RV dysfunction.
Chronic treatment after the first 3 months
Risk factors for VTE recurrence have been classified according to high, intermediate, or low recurrence
risk (table 11).
Potential indications for extended anticoagulation are discussed, including the presence of a minor transient
or reversible risk factor for the index PE, any persisting risk factor, or no identifiable risk factor.
Terminology such as “provoked” versus “unprovoked” PE/VTE is no longer supported by the Guidelines, as
it is potentially misleading and not helpful for decision-making regarding the duration of anticoagulation.
VTE recurrence scores are presented and discussed in parallel with bleeding scores for patients on
anticoagulation treatment (supplementary tables 13 and 14 respectively).
A reduced dose of apixaban or rivaroxaban for extended anticoagulation should be considered after the
first 6 months of treatment.
PE in cancer
Edoxaban or rivaroxaban should be considered as an alternative to LMWH, with a word of caution for
patients with gastrointestinal cancer due to the increased bleeding risk with NOACs.
PE in pregnancy
A dedicated diagnostic algorithm is proposed for suspected PE in pregnancy (figure 7).
Updated information is provided on radiation absorption related to procedures used for diagnosing PE in
pregnancy (table 12).
Long-term sequelae
An integrated model of patient care after PE is proposed to ensure optimal transition from hospital to
community care.
Recommendations on patient care have been extended to the entire spectrum of post-PE symptoms and
functional limitation, not only CTEPH.
A new comprehensive algorithm is proposed for patient follow-up after acute PE (figure 8).
CTEPH: chronic thromboembolic pulmonary hypertension; CTPA: computed tomography pulmonary
angiography; LMWH: low-molecular weight heparin; NOAC(s): non-vitamin K antagonist oral anticoagulant(s);
PE: pulmonary embolism; RV: right ventricular; VKA(s): vitamin K antagonist(s); VTE: venous thromboembolism.
2.2.2. Changes in recommendations between 2014 and 2019
Recommendations




Surgical embolectomy or catheter-directed treatment should be considered as alternatives 
to rescue thrombolytic therapy for patients who deteriorate haemodynamically. IIaIIb
D-dimer measurement and clinical prediction rules should be considered to rule out PE 
during pregnancy or the post-partum period. IIaIIb
Further evaluation may be considered for asymptomatic PE survivors at increased risk for 
CTEPH. IIbIII
CTEPH: chronic thromboembolic pulmonary hypertension; PE: pulmonary embolism. Coloured columns
indicate classes of recommendation (see table 1 for colour coding).
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2.2.3. Main new recommendations 2019
CPET: cardiopulmonary exercise testing; CTEPH: chronic thromboembolic pulmonary hypertension; CUS:
compression ultrasonography; ECMO: extracorporeal membrane oxygenation; LMWH: low-molecular weight
heparin; NOAC(s): non-vitamin K antagonist oral anticoagulant(s); PE: pulmonary embolism; PESI: Pulmonary
Embolism Severity Index; RV: right ventricular; SPECT: single-photon emission computed tomography; sPESI:
simplified Pulmonary Embolism Severity Index; VKA(s): vitamin K antagonist(s); V/Q: ventilation/perfusion
(lung scintigraphy). Coloured columns indicate classes of recommendation (see table 1 for colour coding).
Diagnosis
A D-dimer test, using an age-adjusted cut-off or adapted to clinical probability, should be 
considered as an alternative to the fixed cut-off level. IIa
If a positive proximal CUS is used to confirm PE, risk assessment should be considered to guide 
management. IIa
V/Q SPECT may be considered for PE diagnosis. IIb
Risk assessment
Assessment of the RV by imaging or laboratory biomarkers should be considered, even in the 
presence of a low PESI or a sPESI of 0. IIa
Validated scores combining clinical, imaging, and laboratory prognostic factors may be considered
to further stratify PE severity. IIb
ECMO may be considered, in combination with surgical embolectomy or catheter-directed 
treatment, in refractory circulatory collapse or cardiac arrest. IIb
Treatment in the acute phase
When oral anticoagulation is initiated in a patient with PE who is eligible for a NOAC (apixaban, 
dabigatran, edoxaban, or rivaroxaban), a NOAC is the recommended form of anticoagulant 
treatment.
I
Set-up of multidisciplinary teams for management of high-risk and selected cases of 
intermediate-risk PE should be considered, depending on the resources and expertise
available in each hospital.
Amniotic fluid embolism should be considered in a pregnant or post-partum woman, with 
unexplained haemodynamic instability or respiratory deterioration, and disseminated intravascular 
coagulation.
IIa
Indefinite treatment with a VKA is recommended for patients with antiphospholipid antibody 
syndrome. I
Extended anticoagulation should be considered for patients with no identifiable risk factor for the 
index PE event. IIa
Extended anticoagulation should be considered for patients with a persistent risk factor other than 
antiphospholipid antibody syndrome. IIa
Extended anticoagulation should be considered for patients with a minor transient/reversible risk 
factor for the index PE event. IIa
Thrombolysis or surgical embolectomy should be considered for pregnant women with high-risk PE. IIa
NOACs are not recommended during pregnancy or lactation. III
A reduced dose of apixaban or rivaroxaban should be considered after the first 6 months. IIa
Chronic treatment and prevention of recurrence
Routine clinical evaluation is recommended 3–6 months after acute PE. I
Post-PE care and long-term sequelae 
Edoxaban or rivaroxaban should be considered as an alternative to LMWH, with the exception of 
patients with gastrointestinal cancer. IIa
An integrated model of care is recommended after acute PE to ensure optimal transition from 
hospital to ambulatory care. I
It is recommended that symptomatic patients with mismatched perfusion defects on a V/Q scan >3 
months after acute PE are referred to a pulmonary hypertension/CTEPH expert centre, taking into 




PE in cancer 
PE in pregnancy 
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3. General considerations
3.1. Epidemiology
Venous thromboembolism (VTE), clinically presenting as DVT or PE, is globally the third most frequent
acute cardiovascular syndrome behind myocardial infarction and stroke [2]. In epidemiological studies,
annual incidence rates for PE range from 39 to 115 per 100000 population; for DVT, incidence rates range
from 53 to 162 per 100000 population [3, 4]. Cross-sectional data show that the incidence of VTE is
almost eight times higher in individuals aged ⩾80 years than in the fifth decade of life [3]. In parallel,
longitudinal studies have revealed a rising tendency in annual PE incidence rates [4–7] over time. Together
with the substantial hospital-associated, preventable, and indirect annual expenditures for VTE (an
estimated total of up to EUR 8.5 billion in the European Union) [8], these data demonstrate the
importance of PE and DVT in ageing populations in Europe and other areas of the world. They further
suggest that VTE will increasingly pose a burden on health systems worldwide in the years to come.
PE may cause ⩽300000 deaths per year in the US, ranking high among the causes of cardiovascular
mortality [3]. In six European countries with a total population of 454.4 million, more than 370000 deaths
were related to VTE in 2004, as estimated on the basis of an epidemiological model [9]. Of these patients,
34% died suddenly or within a few hours of the acute event, before therapy could be initiated or take
effect. Of the other patients, death resulted from acute PE that was diagnosed after death in 59% and only
7% of patients who died early were correctly diagnosed with PE before death [9].
Time trend analyses in European, Asian, and North American populations suggest that case fatality rates
of acute PE may be decreasing [4–7, 10, 11]. Increased use of more effective therapies and interventions,
and possibly better adherence to guidelines [12, 13], has most likely exerted a significant positive effect on
the prognosis of PE in recent years. However, there is also a tendency towards overdiagnosis of
(subsegmental or even non-existent) PE in the modern era [14], and this might in turn lead to a false drop
in case fatality rates by inflating the denominator, i.e. the total number of PE cases.
Figure 1 summarizes the existing data on global trends in PE, highlighting increasing incidence rates in
parallel with decreasing case fatality rates over an ∼15 year period.
In children, studies have reported an annual incidence of VTE of between 53 and 57 per 100000 among
hospitalized patients [19, 20], and between 1.4 and 4.9 per 100000 in the community overall [21, 22].
3.2. Predisposing factors
There is an extensive collection of predisposing environmental and genetic factors for VTE; a list of
predisposing (risk) factors is shown in table 3. VTE is considered to be a consequence of the interaction
between patient-related—usually permanent—risk factors and setting-related—usually temporary—risk
factors. Since categorization of temporary and permanent risk factors for VTE is important for assessing
the risk of recurrence, and consequently for decision-making on chronic anticoagulation, it is discussed in
more detail in section 8 of these Guidelines.
Major trauma, surgery, lower-limb fractures and joint replacements, and spinal cord injury are strong
provoking factors for VTE [23, 24]. Cancer is a well-recognized predisposing factor for VTE. The risk of
VTE varies with different types of cancer [25, 26]; pancreatic cancer, haematological malignancies, lung
cancer, gastric cancer, and brain cancer carry the highest risk [27, 28]. Moreover, cancer is a strong risk
factor for all-cause mortality following an episode of VTE [29].
Oestrogen-containing oral contraceptive agents are associated with an elevated VTE risk, and contraceptive
use is the most frequent VTE risk factor in women of reproductive age [30–32]. More specifically, combined
oral contraceptives (containing both an oestrogen and a progestogen) are associated with an approximately
two- to six-fold increase in VTE risk over baseline [32, 33]. In general, the absolute VTE risk remains low in
the majority of the >100 million combined oral contraceptive users worldwide [34]; however, VTE risk
factors, including severe inherited thrombophilia (discussed in section 8) [35], increase this risk.
Third-generation combined oral contraceptives, containing progestogens such as desogestrel or gestodene, are
associated with a higher VTE risk than the second-generation combined oral contraceptives, which contain
progestogens such as levonorgestrel or norgestrel [36, 37]. On the other hand, hormone-releasing intrauterine
devices and some progesterone-only pills (used at contraceptive doses) are not associated with a significant
increase in VTE risk [33, 38]; consequently, and following counselling and full risk assessment, these options
are often proposed to women with a personal or strong family history of VTE.
In post-menopausal women who receive hormone replacement therapy, the risk of VTE varies widely
depending on the formulation used [39].
Infection is a common trigger for VTE [23, 40, 41]. Blood transfusion and erythropoiesis-stimulating
agents are also associated with an increased risk of VTE [23, 42].
https://doi.org/10.1183/13993003.01647-2019 8
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In children, PE is usually associated with DVT and is rarely unprovoked. Serious chronic medical
conditions and central venous lines are considered likely triggers of PE [43].
VTE may be viewed as part of the cardiovascular disease continuum, and common risk factors—such as
cigarette smoking, obesity, hypercholesterolaemia, hypertension, and diabetes mellitus [44–47]—are shared
with arterial disease, notably atherosclerosis [48–51]. However, this may be an indirect association
mediated, at least in part, by the complications of coronary artery disease and, in the case of smoking,
cancer [52, 53]. Myocardial infarction and heart failure increase the risk of PE [54, 55]. Conversely,
patients with VTE have an increased risk of subsequent myocardial infarction and stroke, or peripheral
arterial embolization [56].
3.3. Pathophysiology and determinants of outcome
Acute PE interferes with both circulation and gas exchange. Right ventricular (RV) failure due to acute
pressure overload is considered the primary cause of death in severe PE. Pulmonary artery pressure (PAP)
increases if >30–50% of the total cross-sectional area of the pulmonary arterial bed is occluded by
thromboemboli [57]. PE-induced vasoconstriction, mediated by the release of thromboxane A2 and
serotonin, contributes to the initial increase in pulmonary vascular resistance (PVR) after PE [58].
Anatomical obstruction and hypoxic vasoconstriction in the affected lung area lead to an increase in PVR,
and a proportional decrease in arterial compliance [59].
The abrupt increase in PVR results in RV dilation, which alters the contractile properties of the RV
myocardium via the Frank–Starling mechanism. The increase in RV pressure and volume leads to an
increase in wall tension and myocyte stretch. The contraction time of the RV is prolonged, while
neurohumoral activation leads to inotropic and chronotropic stimulation. Together with systemic
vasoconstriction, these compensatory mechanisms increase PAP, improving flow through the obstructed
pulmonary vascular bed and thus temporarily stabilizing systemic blood pressure (BP). However, the
extent of immediate adaptation is limited, as a non-preconditioned, thin-walled RV is unable to generate a
mean PAP>40 mmHg.
Prolongation of RV contraction time into early diastole in the left ventricle (LV) leads to leftward bowing
of the interventricular septum [60]. The desynchronization of the ventricles may be exacerbated by the
development of right bundle branch block. As a result, LV filling is impeded in early diastole, and this
may lead to a reduction in the cardiac output (CO), and contribute to systemic hypotension and
haemodynamic instability [61].
As described above, excessive neurohumoral activation in PE can be the result of both abnormal RV wall
tension and circulatory shock. The finding of massive infiltrates of inflammatory cells in the RV
myocardia of patients who died within 48 h of acute PE may be explained by high levels of epinephrine
released as a result of the PE-induced “myocarditis” [62]. This inflammatory response might explain the
secondary haemodynamic destabilization that sometimes occurs 24–48 h after acute PE, although early










































































































































FIGURE 1 Trends in annual incidence rates (left panel) and case fatality rates (right panel) of pulmonary embolism around the world, based on
data retrieved from various references [5, 6, 11, 14–17]. Reproduced with permission from [18]. PE: pulmonary embolism; US : United States.
aPE listed as principal diagnosis. bAny listed code for PE was considered.
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Finally, the association between elevated circulating levels of biomarkers of myocardial injury and an adverse
early outcome indicates that RV ischaemia is of pathophysiological significance in the acute phase of PE [63,
64]. Although RV infarction is uncommon after PE, it is likely that the imbalance between oxygen supply and
demand can result in damage to cardiomyocytes, and further reduce contractile forces. Systemic hypotension is
a critical element in this process, leading to impairment of the coronary driving pressure to the overloaded RV.
The detrimental effects of acute PE on the RV myocardium and the circulation are summarized in
Figure 2.
Respiratory failure in PE is predominantly a consequence of haemodynamic disturbances [66]. Low CO
results in desaturation of the mixed venous blood. Zones of reduced flow in obstructed pulmonary arteries,
combined with zones of overflow in the capillary bed served by non-obstructed pulmonary vessels, result in
ventilation/perfusion mismatch, which contributes to hypoxaemia. In about one-third of patients, right-to-left
shunting through a patent foramen ovale can be detected by echocardiography; this is caused by an inverted
pressure gradient between the right atrium (RA) and left atrium, and may lead to severe hypoxaemia, and an
increased risk of paradoxical embolization and stroke [67]. Finally, even if they do not affect haemodynamics,
small distal emboli may create areas of alveolar haemorrhage resulting in haemoptysis, pleuritis, and pleural
effusion, which is usually mild. This clinical presentation is known as “pulmonary infarction”. Its effect on gas
exchange is normally mild, except in patients with pre-existing cardiorespiratory disease.
In view of the above pathophysiological considerations, acute RV failure, defined as a rapidly progressive
syndrome with systemic congestion resulting from impaired RV filling and/or reduced RV flow output [68],
TABLE 3 Predisposing factors for venous thromboembolism (data modified from Rogers et al.
[23] and Anderson and Spencer [24])
Strong risk factors (OR >10)
Fracture of lower limb
Hospitalization for heart failure or atrial fibrillation/flutter (within previous 3 months)
Hip or knee replacement
Major trauma
Myocardial infarction (within previous 3 months)
Previous VTE
Spinal cord injury





Intravenous catheters and leads
Chemotherapy
Congestive heart failure or respiratory failure
Erythropoiesis-stimulating agents




Infection (specifically pneumonia, urinary tract infection, and HIV)
Inflammatory bowel disease




Weak risk factors (OR <2)
Bed rest >3 days
Diabetes mellitus
Arterial hypertension
Immobility due to sitting (e.g. prolonged car or air travel)
Increasing age




HIV: human immunodeficiency virus; OR: odds ratio; VTE: venous thromboembolism.
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is a critical determinant of clinical severity and outcome in acute PE. Accordingly, clinical symptoms, and
signs of overt RV failure and haemodynamic instability, indicate a high risk of early (in-hospital or 30 day)
mortality. High-risk PE is defined by haemodynamic instability and encompasses the forms of clinical
presentation shown in table 4.
As an immediately life-threatening situation, high-risk PE requires an emergency diagnostic (upon
suspicion) and therapeutic (upon confirmation or if the level of suspicion is sufficiently high) strategy, as
outlined in section 7. However, the absence of haemodynamic instability does not exclude beginning (and
possibly progressing) RV dysfunction, and thus an elevated PE-related early risk. In this large population,
further assessment (outlined in sections 5 and 7) is necessary to determine the level of risk and adjust
management decisions accordingly.
4. Diagnosis
The increased awareness of venous thromboembolic disease and the ever-increasing availability of non-invasive
imaging tests, mainly computed tomography (CT) pulmonary angiography (CTPA), have generated a tendency
for clinicians to suspect and initiate a diagnostic workup for PE more frequently than in the past. This
changing attitude is illustrated by the rates of PE confirmation among patients undergoing diagnostic workup:
these were as low as 5% in recent North American diagnostic studies, in sharp contrast to the approximately
50% prevalence reported back in the early 1980s [71]. Therefore, it is critical that, when evaluating
non-invasive diagnostic strategies for PE in the modern era, it is ensured that they are capable of safely
excluding PE in contemporary patient populations with a rather low pre-test probability of the disease [72].
Conversely, a positive test should have an adequate specificity to set the indication for anticoagulant treatment.
4.1. Clinical presentation
The clinical signs and symptoms of acute PE are non-specific. In most cases, PE is suspected in a patient












RV ischaemia, hypoxic injury
Intrapulmonary A-V 
shunting














FIGURE 2 Key factors contributing to haemodynamic collapse and death in acute pulmonary embolism
(modified from Konstantinides et al. [65] with permission). A-V: arterio-venous; BP: blood pressure; CO:
cardiac output; LV - left ventricular; O2: oxygen; RV: right ventricular; TV: tricuspid valve. aThe exact sequence
of events following the increase in RV afterload is not fully understood.
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a rare but important form of clinical presentation, as it indicates central or extensive PE with severely
reduced haemodynamic reserve. Syncope may occur, and is associated with a higher prevalence of
haemodynamic instability and RV dysfunction [76]. Conversely, and according to the results of a recent
study, acute PE may be a frequent finding in patients presenting with syncope (17%), even in the presence
of an alternative explanation [77].
In some cases, PE may be asymptomatic or discovered incidentally during diagnostic workup for another
disease.
Dyspnoea may be acute and severe in central PE; in small peripheral PE, it is often mild and may be
transient. In patients with pre-existing heart failure or pulmonary disease, worsening dyspnoea may be the
only symptom indicative of PE. Chest pain is a frequent symptom of PE and is usually caused by pleural
irritation due to distal emboli causing pulmonary infarction [78]. In central PE, chest pain may have a
typical angina character, possibly reflecting RV ischaemia, and requiring differential diagnosis from an
acute coronary syndrome or aortic dissection.
In addition to symptoms, knowledge of the predisposing factors for VTE is important in determining the
clinical probability of the disease, which increases with the number of predisposing factors present;
however, in 40% of patients with PE, no predisposing factors are found [79]. Hypoxaemia is frequent, but
⩽40% of patients have normal arterial oxygen saturation (SaO2) and 20% have a normal alveolar–arterial
oxygen gradient [80, 81]. Hypocapnia is also often present. A chest X-ray is frequently abnormal and,
although its findings are usually non-specific in PE, it may be useful for excluding other causes of
dyspnoea or chest pain [82]. Electrocardiographic changes indicative of RV strain—such as inversion of
T waves in leads V1–V4, a QR pattern in V1, a S1Q3T3 pattern, and incomplete or complete right bundle
branch block—are usually found in more severe cases of PE [83]; in milder cases, the only abnormality
may be sinus tachycardia, present in 40% of patients. Finally, atrial arrhythmias, most frequently atrial
fibrillation, may be associated with acute PE.
4.2. Assessment of clinical (pre-test) probability
The combination of symptoms and clinical findings with the presence of predisposing factors for VTE allows
the classification of patients with suspected PE into distinct categories of clinical or pre-test probability, which
correspond to an increasing actual prevalence of confirmed PE. This pre-test assessment can be done either
by implicit (empirical) clinical judgement or by using prediction rules. As the post-test (i.e. after an imaging
test) probability of PE depends not only on the characteristics of the diagnostic test itself but also on the
pre-test probability, this is a key step in all diagnostic algorithms for PE.
The value of empirical clinical judgement has been confirmed in several large series [84, 85]. Clinical
judgement usually includes commonplace tests such as chest X-rays and electrocardiograms for differential
diagnosis. However, as clinical judgement lacks standardization, several explicit clinical prediction rules
have been developed. Of these, the most frequently used prediction rules are the revised Geneva rule
(table 5) and the Wells rule (supplementary table 1) [86]. Both prediction rules have been simplified in an
attempt to increase their adoption into clinical practice [87, 88]; the simplified versions have been
externally validated [89, 90].
Regardless of the score used, the proportion of patients with confirmed PE can be expected to be ∼10% in
the low-probability category, 30% in the moderate-probability category, and 65% in the high-probability
category [92]. When the two-level classification is used, the proportion of patients with confirmed PE is
∼12% in the PE-unlikely category and 30% in the PE-likely category [92]. A direct prospective comparison
of these rules confirmed a similar diagnostic performance [89].
TABLE 4 Definition of haemodynamic instability, which delineates acute high-risk pulmonary embolism (one of the following
clinical manifestations at presentation)
(1) Cardiac arrest (2) Obstructive shock [68–70] (3) Persistent hypotension
Need for cardiopulmonary
resuscitation
Systolic BP <90 mmHg or vasopressors required
to achieve a BP ⩾90 mmHg despite adequate
filling status
Systolic BP <90 mmHg or systolic BP drop ⩾40 mmHg,
lasting longer than 15 min and not caused by new-onset
arrhythmia, hypovolaemia, or sepsis
And
End-organ hypoperfusion (altered mental status;
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4.3. Avoiding overuse of diagnostic tests for pulmonary embolism
Searching for PE in every patient with dyspnoea or chest pain may lead to high costs and complications of
unnecessary tests. The Pulmonary Embolism Rule-out Criteria (PERC) were developed for emergency
department patients with the purpose of selecting, on clinical grounds, patients whose likelihood of having
PE is so low that diagnostic workup should not even be initiated [93]. They comprise eight clinical
variables significantly associated with an absence of PE: age <50 years; pulse <100 beats per minute; SaO2
>94%; no unilateral leg swelling; no haemoptysis; no recent trauma or surgery; no history of VTE; and no
oral hormone use. The results of a prospective validation study [94], and those of a randomized
non-inferiority management study [95], suggested safe exclusion of PE in patients with low clinical
probability who, in addition, met all criteria of the PERC rule. However, the low overall prevalence of PE
in these studies [94, 95] does not support the generalizability of the results.
4.4. D-dimer testing
D-dimer levels are elevated in plasma in the presence of acute thrombosis because of simultaneous
activation of coagulation and fibrinolysis. The negative predictive value of D-dimer testing is high, and a
normal D-dimer level renders acute PE or DVT unlikely. On the other hand, the positive predictive value
of elevated D-dimer levels is low and D-dimer testing is not useful for confirmation of PE. D-dimer is also
more frequently elevated in patients with cancer [96, 97], in hospitalized patients [89, 98], in severe
infection or inflammatory disease, and during pregnancy [99, 100]. Accordingly, the number of patients in
whom D-dimer must be measured to exclude one PE (number needed to test) rises from 3 in the general
population of an emergency department to ⩾10 in the specific situations listed above.
As a number of D-dimer assays are available, clinicians should become aware of the diagnostic
performance of the test used in their own hospital. The quantitative enzyme-linked immunosorbent assay
(ELISA) or ELISA-derived assays have a diagnostic sensitivity of ⩾95%, and can be used to exclude PE in
patients with either low or intermediate pre-test probability. In the emergency department, a negative
ELISA D-dimer can, in combination with clinical probability, exclude the disease without further testing in
∼30% of patients with suspected PE [101–103]. Outcome studies have shown that the 3 month
thrombo-embolic risk was <1% in patients with low or intermediate clinical probability who were left
untreated on the basis of a negative test result [104].
4.4.1. Age-adjusted D-dimer cut-offs
The specificity of D-dimer in suspected PE decreases steadily with age to ∼10% in patients >80 years of
age [105]. The use of age-adjusted cut-offs may improve the performance of D-dimer testing in the elderly. A
multinational prospective management study evaluated a previously validated age-adjusted cut-off (age×10 µg/L,
TABLE 5 The revised Geneva clinical prediction rule for pulmonary embolism
Items Clinical decision rule points
Original version [91] Simplified version [87]
Previous PE or DVT 3 1
Heart rate
75–94 b.p.m. 3 1
⩾95 b.p.m. 5 2
Surgery or fracture within the past month 2 1
Haemoptysis 2 1
Active cancer 2 1
Unilateral lower-limb pain 3 1
Pain on lower-limb deep venous palpation and
unilateral oedema
4 1









b.p.m.: beats per minute; DVT: deep vein thrombosis; PE: pulmonary embolism.
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for patients aged >50 years) in a cohort of 3346 patients [106]. Patients with a normal age-adjusted
D-dimer value did not undergo CTPA; they were left untreated and followed for a 3 month period.
Among the 766 patients who were ⩾75 years of age, 673 had a non-high clinical probability. Use of the
age-adjusted (instead of the “standard” 500 µg/L) D-dimer cut-off increased the number of patients in
whom PE could be excluded from 6.4 to 30%, without additional false-negative findings [106].
4.4.2. D-dimer cut-offs adapted to clinical probability
A prospective management trial used the “YEARS” clinical decision rule, which consists of three clinical
items of the Wells score (supplementary table 1)—namely signs of DVT, haemoptysis, and PE more likely
than an alternative diagnosis—plus D-dimer concentrations [107]. PE was considered to be excluded in
patients without clinical items and D-dimer levels <1000 ng/mL, or in patients with one or more clinical
items and D-dimer levels <500 ng/mL. All other patients underwent CTPA. Of the 2946 patients (85%) in
whom PE was ruled out at baseline and who were left untreated, 18 [0.61%, 95% confidence interval (CI)
0.36–0.96%] were diagnosed with symptomatic VTE during the 3 month follow-up. CTPA was avoided in
48% of the included patients using this algorithm, compared to 34% if the Wells rule and a fixed D-dimer
threshold of 500 ng/mL would have been applied [107].
4.4.3. Point-of-care D-dimer assays
In certain situations, notably in community or primary care medicine, “on-the-spot” D-dimer testing may
have advantages over referring a patient to a central laboratory for D-dimer testing. This may particularly
apply to remote areas where access to healthcare is limited [108, 109]. However, point-of-care assays have a
lower sensitivity and negative predictive value compared with laboratory-based D-dimer tests. In a systematic
review and meta-analysis, sensitivity of point-of-care D-dimer assays was 88% (95% CI 83–92%) whereas
conventional laboratory-based D-dimer testing had a sensitivity of at least 95% [110]. As a result,
point-of-care D-dimer assays should only be used in patients with a low pre-test probability. In these
situations, PE could be ruled out in 46% of patients with suspected PE without proceeding to imaging tests
(with a failure rate of 1.5%), as suggested by a prospective study in Dutch primary care [111].
4.5. Computed tomographic pulmonary angiography
Multidetector CTPA is the method of choice for imaging the pulmonary vasculature in patients with
suspected PE. It allows adequate visualization of the pulmonary arteries down to the subsegmental
level [112–114]. The Prospective Investigation On Pulmonary Embolism Diagnosis (PIOPED) II
study observed a sensitivity of 83% and a specificity of 96% for (mainly four-detector) CTPA in PE diagnosis
[115]. PIOPED II also highlighted the influence of pre-test clinical probability on the predictive value of
multidetector CTPA. In patients with a low or intermediate clinical probability of PE, a negative CTPA had
a high negative predictive value for PE (96 and 89%, respectively), but its negative predictive value was only
60% if the pre-test probability was high. Conversely, the positive predictive value of a positive CTPA was
high (92–96%) in patients with an intermediate or high clinical probability, but much lower (58%) in
patients with a low pre-test likelihood of PE [115]. Therefore, clinicians should consider further testing in
case of discordance between clinical judgement and the CTPA result.
Several studies have provided evidence in favour of CTPA as a stand-alone imaging test for excluding PE. Taken
together, the available data suggest that a negative CTPA result is an adequate criterion for the exclusion of PE
in patients with low or intermediate clinical probability of PE. On the other hand, it remains controversial
whether patients with a negative CTPA and a high clinical probability should be further investigated.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a potentially fatal late sequela of PE, but
pre-existing CTEPH should not be missed in patients investigated for suspected acute PE. Signs of
pre-existing CTEPH on CTPA are listed in supplementary table 2; the diagnosis and management of
CTEPH is discussed in section 10.
The major strengths, weaknesses/limitations, and radiation issues related to the use of CTPA in the
diagnosis of PE are summarized in table 6.
4.6. Lung scintigraphy
The planar ventilation/perfusion [V/Q (lung scintigraphy)] scan is an established diagnostic test for suspected
PE. Perfusion scans are combined with ventilation studies, for which multiple tracers such as xenon-133 gas,
krypton-81 gas, technetium-99m-labelled aerosols, or technetium-99m-labelled carbon microparticles
(Technegas) can be used. The purpose of the ventilation scan is to increase specificity: in acute PE,
ventilation is expected to be normal in hypoperfused segments (mismatched). Being a lower-radiation and
contrast medium-sparing procedure, the V/Q scan may preferentially be applied in outpatients with a low
clinical probability and a normal chest X-ray, in young (particularly female) patients, in pregnant women, in
patients with history of contrast medium-induced anaphylaxis, and patients with severe renal failure [116].
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Planar lung scan results are frequently classified according to the criteria established in the PIOPED study
[117]. These criteria were the subject of debate and have been revised [118, 119]. To facilitate
communication with clinicians, a three-tier classification is preferable: normal scan (excluding PE),
high-probability scan (considered diagnostic of PE in most patients), and non-diagnostic scan [120–122].
Prospective clinical outcome studies suggested that it is safe to withhold anticoagulant therapy in patients
with a normal perfusion scan. This was confirmed by a randomized trial comparing the V/Q scan with
CTPA [122]. An analysis from the PIOPED II study suggested that a high-probability V/Q scan could
confirm PE, although other sources suggest that the positive predictive value of a high-probability lung
scan is not sufficient to confirm PE in patients with a low clinical probability [123, 124].
Performing only a perfusion scan might be acceptable in patients with a normal chest X-ray; any
perfusion defect in this situation would be considered a mismatch. The high frequency of non-
diagnostic scans is a limitation because they indicate the necessity for further diagnostic testing. Various
strategies to overcome this problem have been proposed, notably the incorporation of clinical probability.
Although the use of perfusion scanning and chest X-ray with the Prospective Investigative Study of Acute
Pulmonary Embolism Diagnosis (PISAPED) criteria may be associated with a low rate of inconclusive results,
the sensitivity appears too low to exclude PE and thus this approach may be less safe than CTPA [123, 125].
Several studies suggest that data acquisition in single-photon emission CT (SPECT) imaging, with or
without low-dose CT, may decrease the proportion of non-diagnostic scans to as low as 0–5% [121, 126–128].
However, most studies reporting on the accuracy of SPECT are limited by their retrospective design [129, 130]
or the inclusion of SPECT itself in the reference standard [127], and only one study used a validated
diagnostic algorithm [131]. The diagnostic criteria for SPECT also varied; most studies defined PE as one
TABLE 6 Imaging tests for diagnosis of pulmonary embolism
Strengths Weaknesses/limitations Radiation issuesa
CTPA • Readily available around the clock
in most centres
• Excellent accuracy
• Strong validation in prospective
management outcome studies
• Low rate of inconclusive results
(3–5%)
• May provide alternative diagnosis if
PE excluded
• Short acquisition time
• Radiation exposure
• Exposure to iodine contrast:
• limited use in iodine allergy and
hyperthyroidism
• risks in pregnant and breastfeeding
women
• contraindicated in severe renal
failure
• Tendency to overuse because of easy
accessibility
• Clinical relevance of CTPA diagnosis of
subsegmental PE unknown
• Radiation effective dose
3–10 mSvb
• Significant radiation exposure to
young female breast tissue
Planar V/Q scan • Almost no contraindications
• Relatively inexpensive
• Strong validation in prospective
management outcome studies
• Not readily available in all centres
• Interobserver variability in interpretation
• Results reported as likelihood ratios
• Inconclusive in 50% of cases
• Cannot provide alternative diagnosis if
PE excluded
• Lower radiation than CTPA,
effective dose ∼2 mSvb
V/Q SPECT • Almost no contraindications
• Lowest rate of non-diagnostic tests
(<3%)
• High accuracy according to
available data
• Binary interpretation (“PE” versus
“no PE”)
• Variability of techniques
• Variability of diagnostic criteria
• Cannot provide alternative diagnosis if
PE excluded
• No validation in prospective
management outcome studies
• Lower radiation than CTPA,
effective dose ∼2 mSvb
Pulmonary
angiography
• Historical gold standard • Invasive procedure
• Not readily available in all centres
• Highest radiation, effective dose
10–20 mSvb
CTPA: computed tomographic pulmonary angiography; mGy: milligray; mSv: millisieverts; PE: pulmonary embolism; SPECT: single-photon
emission computed tomography; V/Q: ventilation/perfusion (lung scintigraphy). aIn this section, effective radiation dose is expressed in mSv
[dose in mSv = absorbed dose in mGy×radiation weighting factor (1.0 for X-rays)×tissue weighting factor]. This reflects the effective doses of all
organs that have been exposed, that is, the overall radiation dose to the body from the imaging test. Compare with table 12, in which the
absorbed radiation dose is expressed in mGy to reflect the radiation exposure to single organs or to the fetus. bFor comparison, the
whole-body effective dose of a chest X-ray examination is 0.1 mSv [141].
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or two subsegmental perfusion defects without ventilation defects, but these criteria are infrequently used
in clinical practice. In addition, the optimal scanning technique (perfusion SPECT, V/Q SPECT, perfusion
SPECT with non-enhanced CT, or V/Q SPECT with non-enhanced CT) remains to be defined. Finally,
few outcome studies are available, and with incomplete follow-up [132]. Large-scale prospective studies are
needed to validate SPECT techniques.
The major strengths, weaknesses/limitations, and radiation issues related to the use of V/Q scan and V/Q
SPECT in the diagnosis of PE are summarized in table 6.
4.7. Pulmonary angiography
For several decades, pulmonary angiography was the “gold standard” for the diagnosis or exclusion of
acute PE, but it is now rarely performed as less-invasive CTPA offers similar diagnostic accuracy [133].
The diagnosis of acute PE is based on direct evidence of a thrombus in two projections, either as a filling
defect or as amputation of a pulmonary arterial branch [134]. Thrombi as small as 1–2 mm within the
subsegmental arteries can be visualized by digital subtraction angiography, but there is substantial
interobserver variability at this level [135, 136].
Pulmonary angiography is not free of risk. In a study of 1111 patients, procedure-related mortality was 0.5%,
major non-fatal complications occurred in 1%, and minor complications in 5% [137]. The majority of deaths
occurred in patients with haemodynamic compromise or respiratory failure. The amount of contrast agent
should be reduced and non-selective injections avoided in patients with haemodynamic compromise [138].
The major strengths, weaknesses/limitations, and radiation issues related to the use of pulmonary
angiography in the diagnosis of PE are summarized in table 6.
4.8. Magnetic resonance angiography
Magnetic resonance angiography (MRA) has been evaluated for several years regarding suspected PE.
However, the results of large-scale studies [139, 140] show that this technique, although promising, is not
yet ready for clinical practice due to its low sensitivity, the high proportion of inconclusive MRA scans,
and its low availability in most emergency settings. The hypothesis that a negative MRA, combined with
the absence of proximal DVT on compression ultrasonography (CUS), may safely rule out clinically
significant PE is currently being investigated in an ongoing multicentre outcome study [Clinicaltrials.gov
National Clinical Trial (NCT) number 02059551].
4.9. Echocardiography
Acute PE may lead to RV pressure overload and dysfunction, which can be detected by echocardiography.
Given the peculiar geometry of the RV, there is no individual echocardiographic parameter that provides
fast and reliable information on RV size or function. This is why echocardiographic criteria for the
diagnosis of PE have differed between studies. Because of the reported negative predictive value of
40–50%, a negative result cannot exclude PE [124, 142, 143]. On the other hand, signs of RV overload or
dysfunction may also be found in the absence of acute PE, and may be due to concomitant cardiac or
respiratory disease [144].
Echocardiographic findings of RV overload and/or dysfunction are graphically presented in Figure 3. RV
dilation is found in ⩾25% of patients with PE on transthoracic echocardiography (TTE) and is useful for
risk stratification of the disease [145]. More specific echocardiographic findings were reported to retain a
high positive predictive value for PE even in the presence of pre-existing cardiorespiratory disease. Thus,
the combination of a pulmonary ejection acceleration time (measured in the RV outflow tract) <60 ms
with a peak systolic tricuspid valve gradient <60 mmHg (“60/60” sign), or with depressed contractility of the
RV free wall compared to the “echocardiographic” RV apex (McConnell sign), is suggestive of PE [146].
However, these findings are present in only ∼12 and 20% of unselected PE patients, respectively [145].
Detection of echocardiographic signs of RV pressure overload helps to distinguish acute PE from RV free
wall hypokinesia or akinesia due to RV infarction, which may mimic the McConnell sign [147]. It should
be noted that in ∼10% of PE patients, echocardiography can show potentially misleading incidental
findings such as significant LV systolic dysfunction or valvular heart disease [145]. Decreased tricuspid
annular plane systolic excursion (TAPSE) may also be present in PE patients [148, 149].
Echocardiographic parameters of RV function derived from Doppler tissue imaging and wall strain
assessment may also be affected by the presence of acute PE (figure 3). However, they probably have low
sensitivity as stand-alone findings, as they were reported to be normal in haemodynamically stable patients
despite the presence of PE [150, 151].
Echocardiographic examination is not mandatory as part of the routine diagnostic workup in
haemodynamically stable patients with suspected PE [124], although it may be useful in the differential
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diagnosis of acute dyspnoea. This is in contrast to suspected high-risk PE, in which the absence of
echocardiographic signs of RV overload or dysfunction practically excludes PE as the cause of haemodynamic
instability. In the latter case, echocardiography may be of further help in the differential diagnosis of the cause
of shock, by detecting pericardial tamponade, acute valvular dysfunction, severe global or regional LV
dysfunction, aortic dissection, or hypovolaemia [152]. Conversely, in a haemodynamically compromised
patient with suspected PE, unequivocal signs of RV pressure overload, especially with more specific
echocardiographic findings (60/60 sign, McConnell sign, or right-heart thrombi), justify emergency
reperfusion treatment for PE if immediate CT angiography is not feasible in a patient with high clinical
probability and no other obvious causes for RV pressure overload [152].
Mobile right-heart thrombi are detected by TTE or transoesophageal echocardiography (TOE), or by CT
angiography, in <4% of unselected patients with PE [153–155]. Their prevalence may reach 18% among PE
patients in the intensive care setting [156]. Mobile right-heart thrombi essentially confirm the diagnosis of
PE and are associated with high early mortality, especially in patients with RV dysfunction [155, 157–159].
In some patients with suspected acute PE, echocardiography may detect increased RV wall thickness or
tricuspid insufficiency jet velocity beyond values compatible with acute RV pressure overload (>3.8 m/s or
a tricuspid valve peak systolic gradient >60 mmHg) [160]. In these cases, chronic thromboembolic (or
other) pulmonary hypertension (PH) should be included in the differential diagnosis.
4.10. Compression ultrasonography
In the majority of cases, PE originates from DVT in a lower limb, and only rarely from upper-limb DVT
(mostly following venous catheterization). In a study using venography, DVT was found in 70% of patients
with proven PE [161]. Nowadays, lower-limb CUS has largely replaced venography for diagnosing DVT.
CUS has a sensitivity >90% and a specificity of ∼95% for proximal symptomatic DVT [162, 163]. CUS
shows a DVT in 30–50% of patients with PE [162–164], and finding a proximal DVT in patients
suspected of having PE is considered sufficient to warrant anticoagulant treatment without further testing
[165]. However, patients in whom PE is indirectly confirmed by the presence of a proximal DVT should
undergo risk assessment for PE severity and the risk of early death.
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e) 60/60 sign: coexistence of 
acceleration time of pulmonary ejection 
<60 ms and midsystolic “notch” with 
mildly elevated (<60 mmHg) peak 
systolic gradient at the tricuspic valve
f) Right heart mobile 
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h) Decreased peak systolic (S’) 
velocity of tricuspid annulus 
(<9.5 cm/s)
b) Dilated RV with basal RV/LV 
ratio >1.0, and McConnell sign 
(arrow), four chamber view
c) Flattened intraventricle 
septum (arrows) parasternal 
short axis view
d) Distended inferior vena cava 
with diminished inspiratory 
collapsibility, subcostal view
FIGURE 3 Graphic representation of transthoracic echocardiographic parameters in the assessment of right ventricular pressure overload. A′:
peak late diastolic (during atrial contraction) velocity of tricuspid annulus by tissue Doppler imaging; AcT: right ventricular outflow Doppler
acceleration time; Ao: aorta; E′: peak early diastolic velocity of tricuspid annulus by tissue Doppler imaging; IVC: inferior vena cava; LA: left
atrium; LV: left ventricle; RA: right atrium; RiHTh: right heart thrombus (or thrombi); RV: right ventricle/ventricular; S′: peak systolic velocity of
tricuspid annulus by tissue Doppler imaging; TAPSE: tricuspid annular plane systolic excursion; TRPG: tricuspid valve peak systolic gradient.
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In the setting of suspected PE, CUS can be limited to a simple four-point examination (bilateral groin and
popliteal fossa). The only validated diagnostic criterion for DVT is incomplete compressibility of the vein,
which indicates the presence of a clot, whereas flow measurements are unreliable. A positive proximal CUS
result has a high positive predictive value for PE. The high diagnostic specificity (96%) along with a low
sensitivity (41%) of CUS in this setting was shown by a recent meta-analysis [165, 166]. CUS is a useful
procedure in the diagnostic strategy of patients with CT contraindications. The probability of a positive
proximal CUS in suspected PE is higher in patients with signs and symptoms related to the leg veins than
in asymptomatic patients [162, 163].
In patients admitted to the emergency department with haemodynamic instability and suspicion of PE, a
combination of venous ultrasound with cardiac ultrasound may further increase specificity. Conversely, an
echocardiogram without signs of RV dysfunction and a normal venous ultrasound excluded PE with a
high (96%) negative predictive value in one study [167].
For further details on the diagnosis and management of DVT, the reader is referred to the joint consensus
document of the ESC Working Groups of Aorta and Peripheral Vascular Diseases, and Pulmonary
Circulation and Right Ventricular Function [1].
4.11. Recommendations for diagnosis
Suspected PE with haemodynamic instability 
Recommendations Classa Levelb
In suspected high-risk PE, as indicated by the presence of haemodynamic instability, 
bedside echocardiography or emergency CTPA (depending on availability and clinical 
circumstances) is recommended for diagnosis [169]. 
CI
It is recommended that i.v. anticoagulation with UFH, including a weight-adjusted bolus 
injection, be initiated without delay in patients with suspected high-risk PE.
CI
Suspected PE without haemodynamic instability 
The use of validated criteria for diagnosing PE is recommended [12]. BI
Initiation of anticoagulation is recommended without delay in patients with high or 
intermediate clinical probability of PE while diagnostic workup is in progress.
CI
Clinical evaluation 
It is recommended that the diagnostic strategy be based on clinical probability, assessed 
either by clinical judgement or by a validated prediction rule [89, 91, 92, 103, 134, 170–172].
AI
D-dimer 
Plasma D-dimer measurement, preferably using a highly sensitive assay, is recommended 
in outpatients/emergency department patients with low or intermediate clinical probability, 
or those that are PE-unlikely, to reduce the need for unnecessary imaging and irradition 
[101–103, 122, 164, 171, 173, 174].
AI
As an alternative to the fixed D-dimer cut-off, a negative D-dimer test using an age-adjusted 
cut-off (age × 10 μg/L, in patients aged >50 years) should be considered for excluding PE in 
patients with low or intermediate clinical probability, or those that are PE-unlikely [106]. 
BIIa
As an alternative to the fixed or age-adjusted D-dimer cut-off, D-dimer levels adapted to 
clinical probabilityc should be considered to exclude PE [107]. 
BIIa
D-dimer measurement is not recommended in patients with high clinical probability, as a 




It is recommended to reject the diagnosis of PE (without further testing) if CTPA is normal
in a patient with low or intermediate clinical probability, or who is PE-unlikely [101, 122, 164, 
171].
AI
It is recommended to accept the diagnosis of PE (without further testing) if CTPA shows a 
segmental or more proximal filling defect in a patient with intermediate or high clinical 
probability [115].
BI
It should be considered to reject the diagnosis of PE (without further testing) if CTPA is 
normal in a patient with high clinical probability or who is PE-likely [171].
BIIa
Further imaging tests to confirm PE may be considered in cases of isolated subsegmental 
filling defects [115].
CIIb
CT venography is not recommended as an adjunct to CTPA [115, 164]. BIII
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CT: computed tomographic; CTPA: computed tomography pulmonary angiography/angiogram; CUS:
compression ultrasonography; DVT: deep vein thrombosis; i.v.: intravenous; MRA: magnetic resonance
angiography; PE: pulmonary embolism; SPECT: single-photon emission computed tomography; UFH:
unfractionated heparin; V/Q: ventilation/perfusion (lung scintigraphy); VTE: venous thromboembolism.
aClass of recommendation. bLevel of evidence. cD-dimer cut-off levels adapted to clinical probability
according to the YEARS model (signs of DVT, haemoptysis, and whether an alternative diagnosis is less
likely than PE) may be used. According to this model, PE is excluded in patients without clinical items and
D-dimer levels <1000 µg/L, or in patients with one or more clinical items and D-dimer levels <500 µg/L
[107]. dLow level of recommendation in view of the limitations summarized in table 5.
4.12. Computed tomography venography
When using CTPA, it is possible to image the deep veins of the legs during the same acquisition [115].
However, this approach has not been widely validated and the added value of venous imaging is limited
[164]. Moreover, using CT venography is associated with increased radiation doses [168].
5. Assessment of pulmonary embolism severity and the risk of early death
Risk stratification of patients with acute PE is mandatory for determining the appropriate therapeutic
management approach. As described in section 3.3, initial risk stratification is based on clinical symptoms and
signs of haemodynamic instability (table 4), which indicate a high risk of early death. In the large remaining
group of patients with PE who present without haemodynamic instability, further (advanced) risk
stratification requires the assessment of two sets of prognostic criteria: (i) clinical, imaging, and laboratory
indicators of PE severity, mostly related to the presence of RV dysfunction; and (ii) presence of comorbidity
and any other aggravating conditions that may adversely affect early prognosis.
5.1. Clinical parameters of pulmonary embolism severity
Acute RV failure, defined as a rapidly progressive syndrome with systemic congestion resulting from
impaired RV filling and/or reduced RV flow output [68], is a critical determinant of outcome in acute PE.
Tachycardia, low systolic BP, respiratory insufficiency (tachypnoea and/or low SaO2), and syncope, alone or
in combination, have been associated with an unfavourable short-term prognosis in acute PE.
5.2. Imaging of right ventricular size and function
5.2.1. Echocardiography
Echocardiographic parameters used to stratify the early risk of patients with PE are graphically presented
in figure 3, and their prognostic values are summarized in supplementary table 3. Of these, an RV/LV
diameter ratio ⩾1.0 and a TAPSE <16 mm are the findings for which an association with unfavourable
prognosis has most frequently been reported [148].
Overall, evidence for RV dysfunction on echocardiography is found in ⩾25% of unselected patients with
acute PE [145]. Systematic reviews and meta-analyses have suggested that RV dysfunction on
echocardiography is associated with an elevated risk of short-term mortality in patients who appear
V/Q scintigraphy 
It is recommended to reject the diagnosis of PE (without further testing) if the perfusion 
lung scan is normal [75, 122, 134, 174].
AI
It should be considered to accept that the diagnosis of PE (without further testing) if the V/Q 
scan yields high probability for PE [134].
BIIa
A non-diagnostic V/Q scan should be considered as exclusion of PE when combined with a 




V/Q SPECT may be considered for PE diagnosis [121, 126–128]. BIIbd
Lower-limb CUS 
It is recommended to accept the diagnosis of VTE (and PE) if a CUS shows a proximal
DVT in a patient with clinical suspicion of PE [164, 165].
AI
MRA
MRA is not recommended for ruling out PE [139, 140] AIII
If CUS shows only a distal DVT, further testing should be considered to confirm PE [177]. BIIa
If a positive proximal CUS is used to confirm PE, assessment of PE severity should be 
considered to permit risk-adjusted management [178, 179].
CIIa
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haemodynamically stable at presentation [180, 181], but its overall positive predictive value for PE-related
death was low (<10%) in a meta-analysis [180]. This weakness is partly related to the fact that
echocardiographic parameters have proved difficult to standardize [148, 180]. Nevertheless,
echocardiographic assessment of the morphology and function of the RV is widely recognized as a
valuable tool for the prognostic assessment of normotensive patients with acute PE in clinical practice.
In addition to RV dysfunction, echocardiography can identify right-to-left shunt through a patent foramen
ovale and the presence of right heart thrombi, both of which are associated with increased mortality in
patients with acute PE [67, 158]. A patent foramen ovale also increases the risk of ischaemic stroke due to
paradoxical embolism in patients with acute PE and RV dysfunction [182, 183].
5.2.2. Computed tomographic pulmonary angiography
CTPA parameters used to stratify the early risk of patients with PE are summarized in supplementary table
3. Four-chamber views of the heart by CT angiography can detect RV enlargement (RV end-diastolic
diameter and RV/LV ratio measured in the transverse or four-chamber view) as an indicator of RV
dysfunction. The prognostic value of an enlarged RV is supported by the results of a prospective multicentre
cohort study in 457 patients [184]. In that study, RV enlargement (defined as an RV/LV ratio ⩾0.9) was an
independent predictor of an adverse in-hospital outcome, both in the overall population with PE [hazard
ratio (HR) 3.5, 95% CI 1.6–7.7] and in haemodynamically stable patients (HR 3.8, 95% CI 1.3–10.9) [184]. A
meta-analysis of 49 studies investigating >13000 patients with PE confirmed that an increased RV/LV ratio
of ⩾1.0 on CT was associated with a 2.5-fold increased risk for all-cause mortality [odds ratio (OR) 2.5, 95%
CI 1.8–3.5], and with a five-fold risk for PE-related mortality (OR 5.0, 95% CI 2.7–9.2) [185].
Mild RV dilation (RV/LV slightly above 0.9) on CT is a frequent finding (>50% of haemodynamically
stable PE patients [186]), but it probably has minor prognostic significance. However, increasing RV/LV
diameter ratios are associated with rising prognostic specificity [187, 188], even in patients considered to
be at “low” risk on the basis of clinical criteria [186]. Thus, RV/LV ratios ⩾1.0 (instead of 0.9) on CT
angiography may be more appropriate to indicate poor prognosis.
Apart from RV size and the RV/LV ratio, CT may provide further prognostic information based on
volumetric analysis of the heart chambers [189–191] and assessment of contrast reflux to the inferior vena
cava (IVC) [185, 192, 193].
5.3. Laboratory biomarkers
5.3.1. Markers of myocardial injury
Elevated plasma troponin concentrations on admission may be associated with a worse prognosis in the
acute phase of PE. Cardiac troponin I or T elevation are defined as concentrations above the normal
limits, and thresholds depend on the assay used; an overview of the cut-off values has been provided by a
meta-analysis [194]. Of patients with acute PE, between 30 (using conventional assays) [194, 195] and 60%
(using high-sensitivity assays) [196, 197] have elevated cardiac troponin I or T concentrations. A
meta-analysis showed that elevated troponin concentrations were associated with an increased risk of
mortality, both in unselected patients (OR 5.2, 95% CI 3.3–8.4) and in those who were haemodynamically
stable at presentation (OR 5.9, 95% CI 2.7–13.0) [195].
On their own, increased circulating levels of cardiac troponins have relatively low specificity and positive
predictive value for early mortality in normotensive patients with acute PE. However, when interpreted in
combination with clinical and imaging findings, they may improve the identification of an elevated
PE-related risk and the further prognostic stratification of such patients (supplementary table 4). At the
other end of the severity spectrum, high-sensitivity troponin assays possess a high negative predictive value
in the setting of acute PE [197]. For example, in a prospective multicentre cohort of 526 normotensive
patients, high-sensitivity troponin T concentrations <14 pg/mL had a negative predictive value of 98% for
excluding an adverse in-hospital clinical outcome [63]. Age-adjusted high-sensitivity troponin T cut-off
values (⩾14 pg/mL for patients aged <75 years and ⩾45 pg/mL for those ⩾75 years) may further improve
the negative predictive value of this biomarker [196].
Heart-type fatty acid-binding protein (H-FABP), an early and sensitive marker of myocardial injury,
provides prognostic information in acute PE, both in unselected [198, 199] and normotensive patients
[200, 201]. In a meta-analysis investigating 1680 patients with PE, H-FABP concentrations ⩾6 ng/mL were
associated with an adverse short-term outcome (OR 17.7, 95% CI 6.0–51.9) and all-cause mortality (OR
32.9, 95% CI 8.8–123.2) [202].
5.3.2. Markers of right ventricular dysfunction
RV pressure overload due to acute PE is associated with increased myocardial stretch, which leads to the
release of B-type natriuretic peptide (BNP) and N-terminal (NT)-proBNP. Thus, the plasma levels of
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natriuretic peptides reflect the severity of RV dysfunction and haemodynamic compromise in acute PE
[203]. A meta-analysis found that 51% of 1132 unselected patients with acute PE had elevated BNP or
NT-proBNP concentrations on admission; these patients had a 10% risk of early death (95% CI 8.0–13%)
and a 23% (95% CI 20–26%) risk of an adverse clinical outcome [204].
Similar to cardiac troponins (see above), elevated BNP or NT-proBNP concentrations possess low
specificity and positive predictive value (for early mortality) in normotensive patients with PE [205], but
low levels of BNP or NT-proBNP are capable of excluding an unfavourable early clinical outcome, with
high sensitivity and a negative predictive value [180]. In this regard, an NT-proBNP cut-off value <500 pg/mL
was used to select patients for home treatment in a multicentre management study [206]. If emphasis is
placed on increasing the prognostic specificity for an adverse early outcome, higher cut-off values
⩾600 pg/mL might be more appropriate [207].
5.3.3. Other laboratory biomarkers
Lactate is a marker of imbalance between tissue oxygen supply and demand, and consequently of severe
PE with overt or imminent haemodynamic compromise. Elevated arterial plasma levels ⩾2 mmol/L predict
PE-related complications, both in unselected [208] and in initially normotensive [209, 210] PE patients.
Elevated serum creatinine levels and a decreased (calculated) glomerular filtration rate are related to 30 day
all-cause mortality in acute PE [211]. Elevated neutrophil gelatinase-associated lipocalin and cystatin C,
both indicating acute kidney injury, are also of prognostic value [212].
A recent meta-analysis investigating 18616 patients with acute PE found that hyponatraemia predicted
in-hospital mortality (OR 5.6, 95% CI 3.4–9.1) [213].
Vasopressin is released upon endogenous stress, hypotension, and low CO. Its surrogate marker, copeptin,
has been reported to be useful for risk stratification of patients with acute PE [214, 215]. In a single-centre
derivation study investigating 268 normotensive PE patients, copeptin levels ⩾24 pmol/L were associated
with a 5.4-fold (95% CI 1.7–17.6) increased risk of an adverse outcome [216]. These results were
confirmed in 843 normotensive PE patients prospectively included in three European cohorts [217].
5.4. Combined parameters and scores for assessment of pulmonary embolism severity
In patients who present without haemodynamic instability, individual baseline findings may not suffice to
determine and further classify PE severity and PE-related early risk when used as stand-alone parameters. As
a result, various combinations of the clinical, imaging, and laboratory parameters described above have been
used to build prognostic scores, which permit a (semi)quantitative assessment of early PE-related risk of
death. Of these, the Bova [218–221] and the H-FABP (or high-sensitivity troponin T), Syncope, Tachycardia
(FAST) scores [219, 222, 223] have been validated in cohort studies (supplementary table 4). However, their
implications for patient management remain unclear. To date, only a combination of RV dysfunction on an
echocardiogram (or CTPA) with a positive cardiac troponin test has directly been tested as a guide for early
therapeutic decisions (anticoagulation plus reperfusion treatment versus anticoagulation alone) in a large
randomized controlled trial (RCT) of PE patients presenting without haemodynamic instability [224].
5.5. Integration of aggravating conditions and comorbidity into risk assessment of acute
pulmonary embolism
In addition to the clinical, imaging, and laboratory findings, which are directly linked to PE severity and
PE-related early death, baseline parameters related to aggravating conditions and comorbidity are
necessary to assess a patient’s overall mortality risk and early outcome. Of the clinical scores integrating
PE severity and comorbidity, the Pulmonary Embolism Severity Index (PESI) (table 7) is the one that has
been most extensively validated to date [225–228]. The principal strength of the PESI lies in the reliable
identification of patients at low risk for 30 day mortality (PESI classes I and II). One randomized trial
employed a low PESI as the principal inclusion criterion for home treatment of acute PE [178].
In view of the complexity of the original PESI, which includes 11 differently weighed variables, a simplified
version (sPESI; table 7) has been developed and validated [229–231]. As with the original version of the PESI,
the strength of the sPESI lies in the reliable identification of patients at low risk for 30 day mortality. The
prognostic performance of the sPESI has been confirmed in observational cohort studies [227, 228], although
this index has not yet been prospectively used to guide therapeutic management of low-risk PE patients.
The diagnosis of concomitant DVT has been identified as an adverse prognostic factor, being independently
associated with death within the first 3 months after acute PE [232]. In a meta-analysis investigating 8859
patients with PE, the presence of concomitant DVT was confirmed as a predictor of 30 day all-cause mortality
(OR 1.9, 95% CI 1.5–2.4), although it did not predict PE-related adverse outcomes at 90 days [233]. Thus,
concomitant DVT can be regarded as an indicator of significant comorbidity in acute PE.
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5.6. Prognostic assessment strategy
The classification of PE severity and the risk of early (in-hospital or 30 day) death is summarized in table 8.
Risk assessment of acute PE begins upon suspicion of the disease and initiation of the diagnostic workup.
At this early stage, it is critical to identify patients with (suspected) high-risk PE. This clinical setting
necessitates an emergency diagnostic algorithm (figure 4) and immediate referral for reperfusion
treatment, as explained in section 7, and displayed in figure 6 and supplementary figure 1. Testing for
laboratory biomarkers such as cardiac troponins or natriuretic peptides is not necessary for immediate
therapeutic decisions in patients with high-risk PE.
In the absence of haemodynamic instability at presentation, further risk stratification of PE is recommended,
as it has implications for early discharge versus hospitalization or monitoring of the patient (explained in
section 7). Table 8 provides an overview of the clinical, imaging, and laboratory parameters used to
distinguish intermediate- and low-risk PE. The PESI is—in its original or simplified form—the most
extensively validated and most broadly used clinical score to date, as it integrates baseline indicators of the
severity of the acute PE episode with aggravating conditions and the comorbidity of the patient. Overall, a
PESI of class I–II or an sPESI of 0 is a reliable predictor of low-risk PE.
In addition to clinical parameters, patients in the intermediate-risk group who display evidence of both RV
dysfunction (on echocardiography or CTPA) and elevated cardiac biomarker levels in the circulation
(particularly a positive cardiac troponin test) are classified into the intermediate−high-risk category. As will be
discussed in more detail in section 7, close monitoring is recommended in these cases to permit the early
detection of haemodynamic decompensation or collapse, and consequently the need for rescue reperfusion
therapy [179]. Patients in whom the RV appears normal on echocardiography or CTPA, and/or who have
normal cardiac biomarker levels, belong to the intermediate−low-risk category. As an alternative approach,
use of further prognostic scores combining clinical, imaging, and laboratory parameters may be considered to
semi-quantitatively assess the severity of the PE episode, and distinguish intermediate−high-risk and
intermediate−low-risk PE. Supplementary table 4 lists the scores most frequently investigated for this purpose
in observational (cohort) studies; however, none of them has been used in RCTs to date.
A recent meta-analysis included 21 cohort studies with a total of 3295 patients with “low-risk” PE based on a
PESI of I–II or an sPESI of 0 [234]. Overall, 34% (95% CI 30–39%) of them were reported to have signs of RV
dysfunction on echocardiography or CTPA. Data on early mortality were provided in seven studies (1597
patients) and revealed an OR of 4.19 (95% CI 1.39–12.58) for death from any cause in the presence of RV
dysfunction; elevated cardiac troponin levels were associated with a comparable magnitude of risk elevation [234].
TABLE 7 Original and simplified Pulmonary Embolism Severity Index
Parameter Original version [226] Simplified version [229]
Age Age in years 1 point (if age >80 years)
Male sex +10 points –
Cancer +30 points 1 point
Chronic heart failure +10 points 1 point
Chronic pulmonary disease +10 points
Pulse rate ⩾110 b.p.m. +20 points 1 point
Systolic BP <100 mmHg +30 points 1 point
Respiratory rate >30 breaths per min +20 points –
Temperature <36°C +20 points –
Altered mental status +60 points –
Arterial oxyhaemoglobin saturation <90% +20 points 1 point
Risk strataa Class I: ⩽65 points
very low 30 day mortality risk (0–1.6%)
Class II: 66–85 points
low mortality risk (1.7–3.5%)
0 points
30 day mortality risk 1.0%
(95% CI 0.0–2.1%)
Class III: 86–105 points
moderate mortality risk (3.2–7.1%)
Class IV: 106–125 points
high mortality risk (4.0–11.4%)
Class V: >125 points
very high mortality risk (10.0–24.5%)
⩾1 point(s)
30 day mortality risk 10.9%
(95% CI 8.5–13.2%)
BP: blood pressure; b.p.m.: beats per minute; CI: confidence interval. aBased on the sum of points.
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Early all-cause mortality rates (1.8% for RV dysfunction and 3.8% for elevated troponin levels [234]) were in
the lower range of those previously reported for patients with intermediate-risk PE [235]. Until the clinical
implications of such discrepancies are clarified, patients with signs of RV dysfunction or elevated cardiac
biomarkers, despite a low PESI or an sPESI of 0, should be classified into the intermediate–low-risk category.
5.7. Recommendations for prognostic assessment
Recommendations Classa Levelb
Initial risk stratification of suspected or confirmed PE, based on the presence of 
haemodynamic instability, is recommended to identify patients at high risk of early
mortality [218, 219, 235].
BI
In patients without haemodynamic instability, further stratification of patients with acute PE 
into intermediate- and low-risk categories is recommended [179, 218, 219, 235].
BI
In patients without haemodynamic instability, use of clinical prediction rules integrating PE 
severity and comorbidity, preferably the PESI or sPESI, should be considered for risk 
assessment in the acute phase of PE [178, 226, 229].
BIIa
In patients without haemodynamic instability, use of validated scores combining clinical, 
imaging, and laboratory PE-related prognostic factors may be considered to further stratify 
the severity of the acute PE episode [218–223].
CIIb
Assessment of the RV by imaging methodsc or laboratory biomarkersd should be 
considered, even in the presence of a low PESI or a negative sPESI [234].
BIIa
PE: pulmonary embolism; PESI: Pulmonary Embolism Severity Index; RV: right ventricle; sPESI: simplified
Pulmonary Embolism Severity Index. aClass of recommendation. bLevel of evidence. cTransthoracic
echocardiography or computed tomography pulmonary angiography. dCardiac troponins or natriuretic peptides.
6. Treatment in the acute phase
6.1. Haemodynamic and respiratory support
6.1.1. Oxygen therapy and ventilation
Hypoxaemia is one of the features of severe PE, and is mostly due to the mismatch between ventilation
and perfusion. Administration of supplemental oxygen is indicated in patients with PE and SaO2 <90%.
Severe hypoxaemia/respiratory failure that is refractory to conventional oxygen supplementation could be






on TTE or CTPAb
Clinical parameters of PE 
severity and/or comorbidity:
PESI class III–V or sPESI ≥I
Haemodynamic
instabilitya













High + (+)d + (+)
BP: blood pressure; CTPA: computed tomography pulmonary angiography; H-FABP:heart-type fatty acid-binding protein; NT-proBNP:
N-terminal pro B-type natriuretic peptide; PE: pulmonary embolism; PESI: Pulmonary Embolism Severity Index; RV: right ventricular; sPESI:
simplified Pulmonary Embolism Severity Index; TTE: transthoracic echocardiogram. aOne of the following clinical presentations (table 4):
cardiac arrest, obstructive shock (systolic BP <90 mmHg or vasopressors required to achieve a BP ⩾90 mmHg despite an adequate filling
status, in combination with end-organ hypoperfusion), or persistent hypotension (systolic BP <90 mmHg or a systolic BP drop ⩾40 mmHg for
>15 min, not caused by new-onset arrhythmia, hypovolaemia, or sepsis). bPrognostically relevant imaging (TTE or CTPA) findings in patients
with acute PE, and the corresponding cut-off levels, are graphically presented in figure 3, and their prognostic value is summarized in
supplementary table 3. cElevation of further laboratory biomarkers, such as NT-proBNP ⩾600 ng/L, H-FABP ⩾6 ng/mL, or copeptin ⩾24 pmol/
L, may provide additional prognostic information. These markers have been validated in cohort studies but they have not yet been used to guide
treatment decisions in randomized controlled trials. dHaemodynamic instability, combined with PE confirmation on CTPA and/or evidence of RV
dysfunction on TTE, is sufficient to classify a patient into the high-risk PE category. In these cases, neither calculation of the PESI nor
measurement of troponins or other cardiac biomarkers is necessary. eSigns of RV dysfunction on TTE (or CTPA) or elevated cardiac biomarker
levels may be present, despite a calculated PESI of I–II or an sPESI of 0 [234]. Until the implications of such discrepancies for the management
of PE are fully understood, these patients should be classified into the intermediate-risk category.
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explained by right-to-left shunt through a patent foramen ovale or atrial septal defect [67]. Further
oxygenation techniques should also be considered, including high-flow oxygen (i.e. a high-flow nasal
cannula) [236, 237] and mechanical ventilation (non-invasive or invasive) in cases of extreme instability
(i.e. cardiac arrest), taking into consideration that correction of hypoxaemia will not be possible without
simultaneous pulmonary reperfusion.
Patients with RV failure are frequently hypotensive or are highly susceptible to the development of severe
hypotension during induction of anaesthesia, intubation, and positive-pressure ventilation. Consequently,
intubation should be performed only if the patient is unable to tolerate or cope with non-invasive
ventilation. When feasible, non-invasive ventilation or oxygenation through a high-flow nasal cannula
should be preferred; if mechanical ventilation is used, care should be taken to limit its adverse
haemodynamic effects. In particular, positive intrathoracic pressure induced by mechanical ventilation may
reduce venous return and worsen low CO due to RV failure in patients with high-risk PE; therefore,
positive end-expiratory pressure should be applied with caution. Tidal volumes of approximately 6 mL/kg
lean body weight should be used in an attempt to keep the end-inspiratory plateau pressure <30 cm
H2O. If intubation is needed, anaesthetic drugs more prone to cause hypotension should be avoided for
induction.
6.1.2. Pharmacological treatment of acute right ventricular failure
Acute RV failure with resulting low systemic output is the leading cause of death in patients with high-risk
PE. The principles of acute right heart failure management have been reviewed in a statement from the Heart
Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the
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FIGURE 4 Diagnostic algorithm for patients with suspected high-risk pulmonary embolism presenting with
haemodynamic instability. CTPA: computed tomography pulmonary angiography; CUS: compression
ultrasonography; DVT: deep vein thrombosis; LV: left ventricle; PE: pulmonary embolism; RV: right ventricle;
TOE: transoesophageal echocardiography; TTE: transthoracic echocardiogram. aSee table 4 for definition of
haemodynamic instability and high-risk PE. bAncillary bedside imaging tests may include TOE, which may
detect emboli in the pulmonary artery and its main branches; and bilateral venous CUS, which may confirm
DVT and thus VTE. cIn the emergency situation of suspected high-risk PE, this refers mainly to a RV/LV
diameter ratio >1.0; the echocardiographic findings of RV dysfunction, and the corresponding cut-off levels,
are graphically presented in figure 3, and their prognostic value summarized in supplementary table 3.
dIncludes the cases in which the patient’s condition is so critical that it only allows bedside diagnostic tests. In
such cases, echocardiographic findings of RV dysfunction confirm high-risk PE and emergency reperfusion
therapy is recommended.
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If the central venous pressure is low, modest (⩽500 mL) fluid challenge can be used as it may increase the
cardiac index in patients with acute PE [238]. However, volume loading has the potential to over-distend
the RV and ultimately cause a reduction in systemic CO [239]. Experimental studies suggest that
aggressive volume expansion is of no benefit and may even worsen RV function [240]. Cautious volume
loading may be appropriate if low arterial pressure is combined with an absence of elevated filling
pressures. Assessment of central venous pressure by ultrasound imaging of the IVC (a small and/or
collapsible IVC in the setting of acute high-risk PE indicates low volume status) or, alternatively, by
central venous pressure monitoring may help guide volume loading. If signs of elevated central venous
pressure are observed, further volume loading should be withheld.
Use of vasopressors is often necessary, in parallel with (or while waiting for) pharmacological, surgical, or
interventional reperfusion treatment. Norepinephrine can improve systemic haemodynamics by bringing
about an improvement in ventricular systolic interaction and coronary perfusion, without causing a change in
PVR [240]. Its use should be limited to patients in cardiogenic shock. Based on the results of a small series,
the use of dobutamine may be considered for patients with PE, a low cardiac index, and normal BP; however,
raising the cardiac index may aggravate the ventilation/perfusion mismatch by further redistributing flow from
(partly) obstructed to unobstructed vessels [241]. Although experimental data suggest that levosimendan may
restore RV–pulmonary arterial coupling in acute PE by combining pulmonary vasodilation with an increase
in RV contractility [242], no evidence of clinical benefit is available.
Vasodilators decrease PAP and PVR, but may worsen hypotension and systemic hypoperfusion due to
their lack of specificity for the pulmonary vasculature after systemic [intravenous (i.v.)] administration.
Although small clinical studies have suggested that inhalation of nitric oxide may improve the
haemodynamic status and gas exchange of patients with PE [243–245], no evidence for its clinical efficacy
or safety is available to date [246].
6.1.3. Mechanical circulatory support and oxygenation
The temporary use of mechanical cardiopulmonary support, mostly with veno–arterial extracorporeal
membrane oxygenation (ECMO), may be helpful in patients with high-risk PE, and circulatory collapse or
cardiac arrest. Survival of critically ill patients has been described in a number of case series [247–252], but no
RCTs testing the efficacy and safety of these devices in the setting of high-risk PE have been conducted to
date. Use of ECMO is associated with a high incidence of complications, even when used for short periods,
and the results depend on the experience of the centre as well as patient selection. The increased risk of
bleeding related to the need for vascular access should be considered, particularly in patients undergoing
thrombolysis. At present, the use of ECMO as a stand-alone technique with anticoagulation is controversial
[247, 252] and additional therapies, such as surgical embolectomy, have to be considered.
TABLE 9 Treatment of right ventricular failure in acute high-risk pulmonary embolism
Strategy Properties and use Caveats
Volume optimization
Cautious volume loading, saline, or Ringer’s lactate,
⩽500 mL over 15–30 min
Consider in patients with normal–low
central venous pressure (due, for
example, to concomitant
hypovolaemia)
Volume loading can over-distend the RV,
worsen ventricular interdependence,
and reduce CO [239]
Vasopressors and inotropes
Norepinephrine, 0.2–1.0 µg/kg/mina [240] Increases RV inotropy and systemic BP,
promotes positive ventricular
interactions, and restores coronary
perfusion gradient
Excessive vasoconstriction may worsen
tissue perfusion
Dobutamine, 2–20 µg/kg/min [241] Increases RV inotropy, lowers filling
pressures
May aggravate arterial hypotension if
used alone, without a vasopressor;
may trigger or aggravate arrhythmias
Mechanical circulatory support
Veno–arterial ECMO/extracorporeal life support
[251, 252, 258]
Rapid short-term support combined
with oxygenator
Complications with use over longer
periods (>5–10 days), including bleeding
and infections; no clinical benefit unless
combined with surgical embolectomy;
requires an experienced team
CO: cardiac output; BP: blood pressure; ECMO: extracorporeal membrane oxygenation; RV: right ventricle/ventricular. aEpinephrine is used in
cardiac arrest.
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A few cases suggesting good outcomes with use of the Impella® catheter in patients in shock caused by
acute PE have been reported [253, 254].
6.1.4. Advanced life support in cardiac arrest
Acute PE is part of the differential diagnosis of cardiac arrest with non-shockable rhythm against a
background of pulseless electrical activity. In cardiac arrest presumably caused by acute PE, current
guidelines for advanced life support should be followed [255, 256]. The decision to treat for acute PE must
be taken early, when a good outcome is still possible. Thrombolytic therapy should be considered; once a
thrombolytic drug is administered, cardiopulmonary resuscitation should be continued for at least
60–90 min before terminating resuscitation attempts [257].
6.2. Initial anticoagulation
6.2.1. Parenteral anticoagulation
In patients with high or intermediate clinical probability of PE (see section 4), anticoagulation should be
initiated while awaiting the results of diagnostic tests. This is usually done with subcutaneous,
weight-adjusted low-molecular weight heparin (LMWH) or fondaparinux (supplementary table 5), or i.v.
unfractionated heparin (UFH). Based on pharmacokinetic data (supplementary table 6) [259], an equally
rapid anticoagulant effect can also be achieved with a non-vitamin K antagonist oral anticoagulant
(NOAC), and phase III clinical trials have demonstrated the non-inferior efficacy of a single-oral drug
anticoagulation strategy using higher doses of apixaban for 7 days or rivaroxaban for 3 weeks [259–261].
LMWH and fondaparinux are preferred over UFH for initial anticoagulation in PE, as they carry a lower
risk of inducing major bleeding and heparin-induced thrombocytopenia [262–265]. Neither LMWH nor
fondaparinux need routine monitoring of anti-Xa levels. Use of UFH is nowadays largely restricted to
patients with overt haemodynamic instability or imminent haemodynamic decompensation in whom
primary reperfusion treatment will be necessary. UFH is also recommended for patients with serious renal
impairment [creatinine clearance (CrCl) ⩽30 mL/min] or severe obesity. If LMWH is prescribed in
patients with CrCl 15–30 mL/min, an adapted dosing scheme should be used. The dosing of UFH is
adjusted based on the activated partial thromboplastin time (supplementary table 7) [266].
6.2.2. Non-vitamin K antagonist oral anticoagulants
NOACs are small molecules that directly inhibit one activated coagulation factor, which is thrombin for
dabigatran and factor Xa for apixaban, edoxaban, and rivaroxaban. The characteristics of NOACs used in
the treatment of acute PE are summarized in supplementary table 6. Owing to their predictable
bioavailability and pharmacokinetics, NOACs can be given at fixed doses without routine laboratory
monitoring. Compared with vitamin K antagonists (VKAs), there are fewer interactions when NOACs are
given concomitantly with other drugs [259]. In the phase III VTE trials, the dosages of dabigatran,
rivaroxaban, and apixaban were not reduced in patients with mild–moderate renal dysfunction (CrCl
30–60 mL/min), whereas edoxaban was given at a 30 mg dose in these patients. Patients with CrCl<25 mL/min
were excluded from the trials testing apixaban, whereas patients with CrCl<30 mL/min were excluded from
those investigating rivaroxaban, edoxaban, and dabigatran (supplementary table 8).
Phase III trials on the treatment of acute VTE (supplementary table 8), as well as those on extended
treatment beyond the first 6 months (see section 8), demonstrated the non-inferiority of NOACs compared
with the combination of LMWH with VKA for the prevention of symptomatic or lethal VTE recurrence,
along with significantly reduced rates of major bleeding [267]. The different drug regimens tested in these
trials are displayed in supplementary table 8. In a meta-analysis, the incidence rate of the primary efficacy
outcome was 2.0% for NOAC-treated patients and 2.2% for VKA-treated patients [relative risk (RR) 0.88,
95% CI 0.74–1.05] [268]. Major bleeding occurred in 1.1% of NOAC-treated patients and 1.7% of
VKA-treated patients for an RR of 0.60 (95% CI 0.41–0.88). Compared with VKA-treated patients, critical
site major bleeding occurred less frequently in NOAC-treated patients (RR 0.38, 95% CI 0.23– 0.62); in
particular, there was a significant reduction in intracranial bleeding (RR 0.37, 95% CI 0.21–0.68) and in
fatal bleeding (RR 0.36, 95% CI 0.15–0.87) with NOACs compared with VKAs [268].
Suggestions for the anticoagulation management of PE in specific clinical situations, for which conclusive
evidence is lacking, are presented in supplementary table 9.
Practical guidance for clinicians regarding the handling of NOACs and the management of emergency
situations related to their use are regularly updated by the European Heart Rhythm Association [259].
6.2.3. Vitamin K antagonists
VKAs have been the gold standard in oral anticoagulation for more than 50 years. When VKAs are used,
anticoagulation with UFH, LMWH, or fondaparinux should be continued in parallel with the oral anticoagulant for
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⩾5 days and until the international normalized ratio (INR) value has been 2.0–3.0 for 2 consecutive days. Warfarin
may be started at a dose of 10 mg in younger (e.g. aged <60 years) otherwise healthy patients and at a dose ⩽5 mg
in older patients [269]. The daily dose is adjusted according to the INR over the next 5–7 days, aiming for an INR
level of 2.0–3.0. Pharmacogenetic testing may increase the precision of warfarin dosing [270, 271]. When used in
addition to clinical parameters, pharmacogenetic testing improves anticoagulation control and may be associated
with a reduced risk of bleeding, but does not reduce the risk of thromboembolic events or mortality [272].
The implementation of a structured anticoagulant service (most commonly, anticoagulant clinics) appears
to be associated with increased time in the therapeutic range and improved clinical outcome, compared
with control of anticoagulation by the general practitioner [273, 274]. Finally, in patients who are selected
and appropriately trained, self-monitoring of VKA is associated with fewer thrombo-embolic events and
increased time in the therapeutic range compared with usual care [275].
6.3. Reperfusion treatment
6.3.1. Systemic thrombolysis
Thrombolytic therapy leads to faster improvements in pulmonary obstruction, PAP, and PVR in patients
with PE, compared with UFH alone; these improvements are accompanied by a reduction in RV dilation
on echocardiography [276–279]. The greatest benefit is observed when treatment is initiated within 48 h of
symptom onset, but thrombolysis can still be useful in patients who have had symptoms for 6–14 days
[280]. Unsuccessful thrombolysis, as judged by persistent clinical instability and unchanged RV
dysfunction on echocardiography after 36 h, has been reported in 8% of high-risk PE patients [281].
A meta-analysis of thrombolysis trials that included (but were not confined to) patients with high-risk PE,
defined mainly as the presence of cardiogenic shock, indicated a significant reduction in the combined
outcome of mortality and recurrent PE (supplementary table 10). This was achieved with a 9.9% rate of
severe bleeding and a 1.7% rate of intracranial haemorrhage [282].
In normotensive patients with intermediate-risk PE, defined as the presence of RV dysfunction and
elevated troponin levels, the impact of thrombolytic treatment was investigated in the Pulmonary
Embolism Thrombolysis (PEITHO) trial [179]. Thrombolytic therapy was associated with a significant
reduction in the risk of haemodynamic decompensation or collapse, but this was paralleled by an
increased risk of severe extracranial and intracranial bleeding [179]. In the PEITHO trial, 30 day death
rates were low in both treatment groups, although meta-analyses have suggested a reduction in PE-related
and overall mortality of as much as 50–60% following thrombolytic treatment in the intermediate-risk
category (supplementary table 10) [282, 283].
The approved regimens and doses of thrombolytic agents for PE, as well as the contraindications to this
type of treatment, are shown in table 10. Accelerated i.v. administration of recombinant tissue-type
plasminogen activator (rtPA; 100 mg over 2 h) is preferable to prolonged infusions of first-generation
thrombolytic agents (streptokinase and urokinase). Preliminary reports on the efficacy and safety of
reduced-dose rtPA [284, 285] need confirmation by solid evidence before any recommendations can be made
in this regard. UFH may be administered during continuous infusion of alteplase, but should be discontinued
during infusion of streptokinase or urokinase [65]. Reteplase [286], desmoteplase [287], or tenecteplase [179,
278, 279] have also been investigated; at present, none of these agents are approved for use in acute PE.
It remains unclear whether early thrombolysis for (intermediate- or high-risk) acute PE has an impact on
clinical symptoms, functional limitation, or CTEPH at long-term follow-up. A small randomized trial of 83
patients suggested that thrombolysis might improve functional capacity at 3 months compared with
anticoagulation alone [278]. In the PEITHO trial [179], mild persisting symptoms, mainly dyspnoea, were
present in 33% of the patients at long-term (at 41.6±15.7 months) clinical follow-up [288]. However, the
majority of patients (85% in the tenecteplase arm and 96% in the placebo arm) had a low or intermediate
probability—based on the ESC Guidelines definition [289]—of persisting or new-onset PH at
echocardiographic follow-up [288]. Consequently, the findings of this study do not support a role for
thrombolysis with the aim of preventing long-term sequelae (section 10) after intermediate-risk PE, although
they are limited by the fact that clinical follow-up was available for only 62% of the study population.
6.3.2. Percutaneous catheter-directed treatment
Mechanical reperfusion is based on the insertion of a catheter into the pulmonary arteries via the femoral
route. Different types of catheters (summarized in supplementary table 11) are used for mechanical
fragmentation, thrombus aspiration, or more commonly a pharmacomechanical approach combining
mechanical or ultrasound fragmentation of the thrombus with in situ reduced-dose thrombolysis.
Most knowledge about catheter-based embolectomy is derived from registries and pooled results from case series
[290, 291]. The overall procedural success rates (defined as haemodynamic stabilization, correction of hypoxia,
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and survival to hospital discharge) of percutaneous catheter-based therapies reported in these studies have reached
87% [292]; however, these results may be subject to publication bias. One RCT compared conventional
heparin-based treatment and a catheter-based therapy combining ultrasound-based clot fragmentation with
low-dose in situ thrombolysis in 59 patients with intermediate-risk PE. In that study, ultrasound-assisted
thrombolysis was associated with a larger decrease in the RV/LV diameter ratio at 24 h, without an increased risk
of bleeding [293]. Data from two prospective cohort studies [294, 295] and a registry [296], with a total of 352
patients, support the improvement in RV function, lung perfusion, and PAP in patients with intermediate- or
high-risk PE using this technique. Intracranial haemorrhage was rare, although the rate of Global Utilization of
Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) severe and moderate
bleeding complications was 10% in one of these cohorts [294]. These results should be interpreted with caution,
considering the relatively small numbers of patients treated, the lack of studies directly comparing catheter-directed
with systemic thrombolytic therapy, and the lack of data from RCTs on clinical efficacy outcomes.
6.3.3. Surgical embolectomy
Surgical embolectomy in acute PE is usually carried out with cardiopulmonary bypass, without aortic
cross-clamping and cardioplegic cardiac arrest, followed by incision of the two main pulmonary arteries with
the removal or suction of fresh clots. Recent reports have indicated favourable surgical results in high-risk PE,
with or without cardiac arrest, and in selected cases of intermediate-risk PE [297–300]. Among 174322
patients hospitalized between 1999 and 2013 with a diagnosis of PE in New York state, survival and recurrence
rates were compared between patients who underwent thrombolysis (n=1854) or surgical embolectomy
(n=257) as first-line therapy [297]. Overall, there was no difference between the two types of reperfusion
treatment regarding 30 day mortality (15 and 13%, respectively), but thrombolysis was associated with a higher
risk of stroke and re-intervention at 30 days. No difference was found in terms of 5 year actuarial survival, but
thrombolytic therapy was associated with a higher rate of recurrent PE requiring readmission compared with
surgery (7.9 versus 2.8%). However, the two treatments were not randomly allocated in this observational
retrospective study, and the patients referred for surgery may have been selected. An analysis of the Society of
Thoracic Surgery Database with multicentre data collection, including 214 patients submitted for surgical
embolectomy for high- (n=38) or intermediate-risk (n=176) PE, revealed an in-hospital mortality rate of 12%,
with the worst outcome (32%) in the group experiencing pre-operative cardiac arrest [299].
Recent experience appears to support combining ECMO with surgical embolectomy, particularly in
patients with high-risk PE with or without the need for cardiopulmonary resuscitation. Among patients
who presented with intermediate-risk PE (n=28), high-risk PE without cardiac arrest (n=18), and PE with
cardiac arrest (n=9), the in-hospital and 1 year survival rates were 93 and 91%, respectively [300].
6.4. Multidisciplinary pulmonary embolism teams
The concept of multidisciplinary rapid-response teams for the management of “severe” (high-risk and
selected cases of intermediate-risk) PE emerged in the USA, with increasing acceptance by the medical
TABLE 10 Thrombolytic regimens, doses, and contraindications
Molecule Regimen Contraindications to fibrinolysis
rtPA 100 mg over 2 h Absolute
History of haemorrhagic stroke or stroke of unknown origin
Ischaemic stroke in previous 6 months
Central nervous system neoplasm




Transient ischaemic attack in previous 6 months
Oral anticoagulation
Pregnancy or first post-partum week
Non-compressible puncture sites
Traumatic resuscitation




0.6 mg/kg over 15 min (maximum dose 50 mg)a
Streptokinase 250000 IU as a loading dose over 30 min,
followed by 100000 IU/h over 12–24 h
Accelerated regimen: 1.5 million IU over 2 h
Urokinase 4400 IU/kg as a loading dose over 10 min,
followed by 4400 IU/kg/h over 12–24 h
Accelerated regimen: 3 million IU over 2 h
BP: blood pressure; IU: international units; rtPA, recombinant tissue-type plasminogen activator. aThis is the accelerated regimen for rtPA in
pulmonary embolism; it is not officially approved, but it is sometimes used in extreme haemodynamic instability such as cardiac arrest.
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community and implementation in hospitals in Europe and worldwide. Set-up of PE response teams
(PERTs) is encouraged, as they address the needs of modern systems-based healthcare [301]. A PERT
brings together a team of specialists from different disciplines including, for example, cardiology,
pulmonology, haematology, vascular medicine, anaesthesiology/intensive care, cardiothoracic surgery, and
(interventional) radiology. The team convenes in real time (face-to-face or via web conference) to enhance
clinical decision-making. This allows the formulation of a treatment plan and facilitates its immediate
implementation [301]. The exact composition and operating mode of a PERT are not fixed, depending on
the resources and expertise available in each hospital for the management of acute PE.
6.5. Vena cava filters
The aim of vena cava interruption is to mechanically prevent venous clots from reaching the pulmonary
circulation. Most devices in current use are inserted percutaneously and can be retrieved after several
weeks or months, or left in place over the long-term, if needed. Potential indications include VTE and
absolute contraindication to anticoagulant treatment, recurrent PE despite adequate anticoagulation, and
primary prophylaxis in patients with a high risk of VTE. Other potential indications for filter placement,
including free-floating thrombi, have not been confirmed in patients without contraindications to
therapeutic anticoagulation.
Only two phase III randomized trials have compared anticoagulation with or without vena cava
interruption in patients with proximal DVT, with or without associated PE [302–304]. In the Prevention
of Recurrent Pulmonary Embolism by Vena Cava Interruption (PREPIC) study, insertion of a permanent
vena cava filter was associated with a significant reduction in the risk of recurrent PE and a significant
increase in the risk of DVT, without a significant difference in the risk of recurrent VTE or death [303, 304].
The PREPIC-2 trial randomized 399 patients with PE and venous thrombosis to receive anticoagulant
treatment, with or without a retrievable vena cava filter. In this study, the rate of recurrent VTE was low in
both groups and did not differ between groups [302]. A systematic review and meta-analysis of published
reports on the efficacy and safety of vena cava filters included 11 studies, with a total of 2055 patients who
received a filter versus 2149 controls [305]. Vena cava filter placement was associated with a 50% decrease
in the incidence of PE and an ∼70% increase in the risk of DVT over time. Neither all-cause mortality nor
PE-related mortality differed between patients with or without filter placement.
The broad indication for placement of a venous filter in patients with recent (<1 month) proximal DVT
and an absolute contraindication to anticoagulant treatment is based mainly on the perceived high risk of
recurrent PE in this setting, and the lack of other treatment options.
Complications associated with vena cava filters are common and can be serious. A systematic literature
review revealed penetration of the venous wall in 1699 (19%) of 9002 procedures; of these cases, 19%
showed adjacent organ involvement and ⩾8% were symptomatic [306]. Lethal complications were rare
(only two cases), but 5% of the patients required major interventions such as surgical removal of the filter,
endovascular stent placement or embolization, endovascular retrieval of the permanent filter, or
percutaneous nephrostomy or ureteral stent placement [306]. Further reported complications include filter
fracture and/or embolization, and DVT occasionally extending up to the vena cava [303, 307, 308].
6.6. Recommendations for acute-phase treatment of high-risk pulmonary embolisma
Recommendations Classb Levelc
It is recommended that anticoagulation with UFH, including a weight-adjusted bolus 
injection, be initiated without delay in patients with high-risk PE. 
CI
Systemic thrombolytic therapy is recommended for high-risk PE [282]. BI
Surgical pulmonary embolectomy is recommended for patients with high-risk PE, in whom 
thrombolysis is contraindicated or has failedd [281].
CI
Percutaneous catheter-directed treatment should be considered for patients with high-risk 
PE, in whom thrombolysis is contraindicated or has failedd. 
CIIa
Norepinephrine and/or dobutamine should be considered in patients with high-risk PE. CIIa
ECMO may be considered, in combination with surgical embolectomy or catheter-directed 
treatment, in patients with PE and refractory circulatory collapse or cardiac arrestd [252].
CIIb
ECMO: extracorporeal membrane oxygenation; PE: pulmonary embolism; UFH: unfractionated heparin.
aSee table 4 for definition of high-risk PE. After haemodynamic stabilization of the patient, continue with
anticoagulation treatment as in intermediate- or low-risk PE (section 6.7). bClass of recommendation.
cLevel of evidence. dIf appropriate expertise and resources are available on-site.
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6.7. Recommendations for acute-phase treatment of intermediate- or low-risk pulmonary embolism
CrCl: creatinine clearance; INR: international normalized ratio; LMWH: low-molecular weight heparin;
NOAC(s): non-vitamin K antagonist oral anticoagulant(s); PE: pulmonary embolism; UFH: unfractionated
heparin; VKA: vitamin K antagonist. aClass of recommendation. bLevel of evidence. cSee table 8 for definition
of the PE severity and PE-related risk. dDabigatran is not recommended in patients with CrCl <30 mL/min.
Edoxaban should be given at a dose of 30 mg once daily in patients with CrCl of 15–50 mL/min and is not
recommended in patients with CrCl <15 mL/min. Rivaroxaban and apixaban are to be used with caution in
patients with CrCl 15–29 mL/min, and their use is not recommended in patients with CrCl <15 mL/min.
eIf appropriate expertise and resources are available on-site. fThe risk-to-benefit ratios of surgical
embolectomy or catheter-directed procedures have not yet been established in intermediate- or low-risk PE.
6.8. Recommendations for multidisciplinary pulmonary embolism teams
Recommendations Classa Levelb
Set-up of a multidisciplinary team and a programme for the management of high- and (in 
selected cases) intermediate-risk PE should be considered, depending on the resources and 
expertise available in each hospital.
CIIa
PE: pulmonary embolism. aClass of recommendation. bLevel of evidence.
6.9. Recommendations for inferior vena cava filters
Recommendations Classa Levelb
IVC filters should be considered in patients with acute PE and absolute contraindications to 
anticoagulation.
CIIa
IVC filters should be considered in cases of PE recurrence despite therapeutic 
anticoagulation.
CIIa
Routine use of IVC filters is not recommended [302–304] AIII
IVC: inferior vena cava; PE: pulmonary embolism. aClass of recommendation. bLevel of evidence.
6.10. Recommendations for early discharge and home treatment
Recommendations Classa Levelb
Carefully selected patients with low-risk PE should be considered for early discharge and 
continuation of treatment at home, if proper outpatient care and anticoagulant treatment 
can be providedc [178, 206, 317–319].
AIIa
PE: pulmonary embolism. aClass of recommendation. bLevel of evidence. cSee section 7 and figure 6 for
further guidance on defining low-risk PE and decision-making.
Recommendations 
Initiation of anticoagulation 
Classa Levelb
Initiation of anticoagulation is recommended without delay in patients with high or 
intermediate clinical probability of PEc, while diagnostic workup is in progress.
CI
If anticoagulation is initiated parenterally, LMWH or fondaparinux is recommended (over 
UFH) for most patients [262, 309–311].
AI
When oral anticoagulation is started in a patient with PE who is eligible for a NOAC 
(apixaban, dabigatran, edoxaban, or rivaroxaban), a NOAC is recommended in preference to 
a VKA [260, 261, 312–314].
AI
When patients are treated with a VKA, overlapping with parenteral anticoagulation is 
recommended until an INR of 2.5 (range 2.0–3.0) is reached [315, 316].
AI
NOACs are not recommended in patients with severe renal impairment,d during pregnancy 
and lactation, and in patients with antiphospholipid antibody syndrome [260, 261, 312–314].
CIII
Reperfusion treatment 
Rescue thrombolytic therapy is recommended for patients with haemodynamic deterioration 
on anticoagulation treatment [282].
BI
As an alternative to rescue thrombolytic therapy, surgical embolectomye or percutaneous 
catheter-directed treatmente should be considered for patients with haemodynamic 
deterioration on anticoagulation treatment.
CIIa
Routine use of primary systemic thrombolysis is not recommended in patients with 
intermediate- or low-risk PEc,f [179].
BIII
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7. Integrated risk-adapted diagnosis and management
7.1. Diagnostic strategies
Various combinations of clinical assessments, plasma D-dimer measurements, and imaging tests have been
proposed and validated for PE diagnosis. These strategies have been tested in patients presenting with
suspected PE in the emergency department or during their hospital stay [101, 164, 171, 320], and more
recently in the primary care setting [111]. Withholding of anticoagulation without adherence to
evidence-based diagnostic strategies was associated with a significant increase in the number of VTE
episodes and sudden cardiac death at 3 month follow-up [12]. The most straightforward diagnostic
algorithms for suspected PE—with and without haemodynamic instability—are presented in figures 4 and 5,
respectively. However, it is recognized that the diagnostic approach for suspected PE may vary, depending
on the availability of, and expertise in, specific tests in various hospitals and clinical settings.
The diagnostic strategy for suspected acute PE in pregnancy is discussed in section 9.
7.1.1. Suspected pulmonary embolism with haemodynamic instability
The proposed strategy is shown in figure 4. The clinical probability is usually high and the differential
diagnosis includes cardiac tamponade, acute coronary syndrome, aortic dissection, acute valvular
Suspected PE in a patient without haemodynamic instabilitya
Assess clinical probability of PE
Clinical judgement or prediction ruleb
Low or intermediate clinical probability,
or PE unlikely
PositiveNegative










FIGURE 5 Diagnostic algorithm for patients with suspected pulmonary embolism without haemodynamic
instability. CTPA: computed tomography pulmonary angiography/angiogram; PE: pulmonary embolism. aThe
proposed diagnostic strategy for pregnant women with suspected acute PE is discussed in section 9. bTwo
alternative classification schemes may be used for clinical probability assessment, i.e. a three-level scheme
(clinical probability defined as low, intermediate, or high) or a two-level scheme (PE unlikely or PE likely).
When using a moderately sensitive assay, D-dimer measurement should be restricted to patients with low
clinical probability or a PE-unlikely classification, while highly sensitive assays may also be used in patients
with intermediate clinical probability of PE due to a higher sensitivity and negative predictive value. Note that
plasma D-dimer measurement is of limited use in suspected PE occurring in hospitalized patients.
cTreatment refers to anticoagulation treatment for PE. dCTPA is considered diagnostic of PE if it shows PE at
the segmental or more proximal level. eIn case of a negative CTPA in patients with high clinical probability,
investigation by further imaging tests may be considered before withholding PE-specific treatment.
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dysfunction, and hypovolaemia. The most useful initial test in this situation is bedside TTE, which will
yield evidence of acute RV dysfunction if acute PE is the cause of the patient’s haemodynamic
decompensation. In a highly unstable patient, echocardiographic evidence of RV dysfunction is sufficient
to prompt immediate reperfusion without further testing. This decision may be strengthened by the (rare)
visualization of right heart thrombi [155, 157, 321, 322]. Ancillary bedside imaging tests include TOE,
which may allow direct visualization of thrombi in the pulmonary artery and its main branches, especially
in patients with RV dysfunction. TOE should be cautiously performed in hypoxaemic patients. Moreover,
bedside CUS can detect proximal DVT. As soon as the patient is stabilized using supportive treatment,
final confirmation of the diagnosis by CT angiography should be sought.
For unstable patients admitted directly to the catheterization laboratory with suspected acute coronary
syndrome, pulmonary angiography may be considered as a diagnostic procedure after the acute coronary
syndrome has been excluded, provided that PE is a probable diagnostic alternative and particularly if
percutaneous catheter-directed treatment is a therapeutic option.
7.1.2. Suspected pulmonary embolism without haemodynamic instability
7.1.2.1. Strategy based on computed tomographic pulmonary angiography
The proposed strategy based on CTPA is shown in figure 5. In patients admitted to the emergency
department, measurement of plasma D-dimer is the logical first step following the assessment of clinical
probability and allows PE to be ruled out in ∼30% of outpatients. D-dimer should not be measured in
patients with a high clinical probability of PE, owing to a low negative predictive value in this population
[323]. It is also less useful in hospitalized patients because the number that needs to be tested to obtain a
clinically relevant negative result is high.
In most centres, multidetector CTPA is the second-line test in patients with an elevated D-dimer level and
the first-line test in patients with a high clinical probability of PE. CTPA is considered to be diagnostic of
PE when it shows a clot at least at the segmental level of the pulmonary arterial tree. False-negative results
of CTPA have been reported in patients with a high clinical probability of PE [115]; however, such
discrepancies are infrequent and the 3 month thromboembolic risk was low in these patients [171].
Accordingly, both the necessity of performing further tests and the nature of these tests remain
controversial in these clinical situations.
7.1.2.2. Strategy based on ventilation/perfusion scintigraphy
In hospitals in which V/Q scintigraphy is readily available, it is a valid option for patients with an elevated
D-dimer and a contraindication to CTPA. Also, V/Q scintigraphy may be preferred over CTPA to avoid
unnecessary radiation, particularly in younger patients and in female patients in whom thoracic CT might
raise the lifetime risk of breast cancer [324]. V/Q lung scintigraphy is diagnostic (with either normal- or
high-probability findings) in ∼30–50% of emergency ward patients with suspected PE [75, 122, 134, 325]. The
proportion of diagnostic V/Q scans is higher in patients with a normal chest X-ray, and this might support
the use of a V/Q scan as a first-line imaging test for PE in younger patients, depending on local availability
[326]. The number of patients with inconclusive findings may further be reduced by taking into account
clinical probability. Thus, patients with a non-diagnostic lung scan and low clinical probability of PE have a
low prevalence of confirmed PE [124, 325], and the negative predictive value of this combination is further
increased by the absence of a DVT on lower-limb CUS. If a high-probability lung scan is obtained from a
patient with low clinical probability of PE, confirmation by other tests should be considered.
7.2. Treatment strategies
7.2.1. Emergency treatment of high-risk pulmonary embolism
The algorithm for a risk-adjusted therapeutic approach to acute PE is shown in figure 6; an emergency
management algorithm specifically for patients with suspected acute high-risk PE is proposed in
supplementary figure 1. Primary reperfusion treatment, in most cases systemic thrombolysis, is the
treatment of choice for patients with high-risk PE. Surgical pulmonary embolectomy or percutaneous
catheter-directed treatment are alternative reperfusion options in patients with contraindications to
thrombolysis, if expertise with either of these methods and the appropriate resources are available on-site.
Following reperfusion treatment and haemodynamic stabilization, patients recovering from high-risk PE
can be switched from parenteral to oral anticoagulation. As patients belonging to this risk category were
excluded from the phase III NOAC trials, the optimal time point for this transition has not been
determined by existing evidence but should instead be based on clinical judgement. The specifications
concerning the higher initial dose of apixaban or rivaroxaban (for 1 and 3 weeks after PE diagnosis,
respectively), or the minimum overall period (5 days) of heparin anticoagulation before switching to
dabigatran or edoxaban, must be followed (see supplementary table 8 for tested and approved regimens).
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Distinguish low- from intermediate-risk PEb
CHECK      and     :
     CLINICAL SIGNS OF PE SEVERITY,
OR SERIOUS COMORBIDITY?
     PESI Class III-IV or sPESI ≥Ic
     Alternatively: ≥I Hestia criterion of PE
severity or comorbidity fulfilledd
No other reasons for
hospitalization?g
Family or social support?g






















or      present Neither      nor      present:
LOW RISKb
     RV DYSFUNCTION 
ON TTE OR CTPA?e




FIGURE 6 Central Illustration. Risk-adjusted management strategy for acute pulmonary embolism. CTPA: computed tomography pulmonary
angiography/angiogram; PE: pulmonary embolism; PESI: Pulmonary Embolism Severity Index; RV: right ventricular; sPESI: simplified Pulmonary
Embolism Severity Index; TTE: transthoracic echocardiogram. aSee also emergency management algorithm shown in the supplementary data.
bRefer to table 8 for definition of high, intermediate-high-, intermediate-low-, and low-risk PE. cCancer, heart failure and chronic lung disease
are included in the PESI and sPESI (table 7). dSee supplementary table 12 for the Hestia criteria. ePrognostically relevant imaging (TTE or CTPA)
findings in patients with acute PE, are graphically presented in Figure 3. fA cardiac troponin test may already have been performed during initial
diagnostic work-up. gIncluded in the Hestia criteria.
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7.2.2. Treatment of intermediate-risk pulmonary embolism
For most cases of acute PE without haemodynamic compromise, parenteral or oral anticoagulation
(without reperfusion techniques) is adequate treatment. As shown in figure 6, normotensive patients with
at least one indicator of elevated PE-related risk, or with aggravating conditions or comorbidity, should be
hospitalized. In this group, patients with signs of RV dysfunction on echocardiography or CTPA
(graphically presented in figure 3), accompanied by a positive troponin test, should be monitored over the
first hours or days due to the risk of early haemodynamic decompensation and circulatory collapse [179].
Routine primary reperfusion treatment, notably full-dose systemic thrombolysis, is not recommended, as
the risk of potentially life-threatening bleeding complications appears too high for the expected benefits
from this treatment [179]. Rescue thrombolytic therapy or, alternatively, surgical embolectomy or
percutaneous catheter-directed treatment should be reserved for patients who develop signs of
haemodynamic instability. In the PEITHO trial, the mean time between randomization and death or
haemodynamic decompensation was 1.79±1.60 days in the placebo (heparin-only) arm [179]. Therefore, it
appears reasonable to leave patients with intermediate–high-risk PE on LMWH anticoagulation over the
first 2–3 days and ensure that they remain stable before switching to oral anticoagulation. As mentioned in
the previous section, the specifications concerning the increased initial dose of apixaban or rivaroxaban, or
the minimum overall period of heparin anticoagulation before switching to dabigatran or edoxaban, must
be followed.
Suggestions for the anticoagulation and overall management of acute PE in specific clinical situations, for
which conclusive evidence is lacking, are presented in supplementary table 9.
7.2.3. Management of low-risk pulmonary embolism: triage for early discharge and home treatment
As a general rule, early discharge of a patient with acute PE and continuation of anticoagulant treatment
at home should be considered if three sets of criteria are fulfilled: (i) the risk of early PE-related death or
serious complications is low (section 5); (ii) there is no serious comorbidity or aggravating condition(s)
(section 5) that would mandate hospitalization; and (iii) proper outpatient care and anticoagulant
treatment can be provided, considering the patient’s (anticipated) compliance, and the possibilities offered
by the healthcare system and social infrastructure.
Randomized trials and prospective management cohort studies that investigated the feasibility and safety
of early discharge, and home treatment, of PE adhered to these principles, even though slightly different
criteria or combinations thereof were used to ensure the above three requirements.
The Hestia exclusion criteria (supplementary table 12) represent a checklist of clinical parameters or
questions that can be obtained/answered at the bedside. They integrate aspects of PE severity, comorbidity,
and the feasibility of home treatment. If the answer to one or more of the questions is “yes”, then the patient
cannot be discharged early. In a single-arm management trial that used these criteria to select candidates for
home treatment, the 3 month rate of recurrent VTE was 2.0% (0.8–4.3%) in patients with acute PE who were
discharged within 24 h [317]. In a subsequent non-inferiority trial that randomized 550 patients to direct
discharge based on the Hestia criteria alone versus additional NT-proBNP testing and discharge if levels were
⩽500 pg/mL, the primary outcome (30 day PE- or bleeding-related mortality, cardiopulmonary resuscitation,
or admission to an intensive care unit) was very low in both arms. The results suggest no incremental value
of natriuretic-peptide testing in patients who are eligible for home treatment based on the Hestia criteria,
although the study was not powered to exclude this possibility [318].
The PESI and its simplified form, the sPESI (table 7), also integrate clinical parameters of PE severity and
comorbidity to permit assessment of overall 30 day mortality. Compared with the Hestia criteria, the PESI is
more standardized, but it contains a less-comprehensive list of aggravating conditions; moreover, the sPESI
excludes all patients with cancer from the low-risk category (compare table 7 with supplementary table 12).
The PESI was not primarily developed as a tool to select candidates for home treatment, but it has been used
—in combination with additional feasibility criteria—in a trial of 344 patients randomized to inpatient versus
outpatient treatment of PE [178]. One (0.6%) patient in each treatment group died within 90 days [178].
In patients who were included in prospective cohort studies and treated at home, with or without a short
hospitalization period, the 3 month rates of thromboembolic recurrence, major bleeding, and death were
1.75, 1.43, and 2.83%, respectively [327].
In summary, the currently available evidence indicates that both the Hestia rule and the PESI or sPESI
appear capable of reliably identifying patients who are (i) at low PE-related risk, and (ii) free of serious
comorbidity. Consequently, either may be used for clinical triage according to local experience and
preference. If a PESI- or sPESI-based approach is chosen, it must be combined with assessment of the
feasibility of early discharge and home treatment; this assessment is already integrated into the Hestia
criteria.
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A more difficult decision related to immediate or early discharge is whether the exclusion of intermediate-risk
PE on clinical grounds alone is adequate, or whether the assessment of RV dysfunction or myocardial injury
(see section 5) by an imaging test or a laboratory biomarker is necessary to provide maximal safety for the
patient in this “vulnerable” early period. A systematic review and meta-analysis of cohort studies suggested
that the prognostic sensitivity is increased further when clinical criteria (e.g. PESI or sPESI) are combined
with imaging findings, or laboratory biomarker levels [234]. A multicentre prospective management trial
tested this hypothesis, investigating the efficacy and safety of early discharge, and ambulatory rivaroxaban
treatment, in patients selected by clinical criteria and an absence of RV dysfunction. Overall, ∼20% of the
screened unselected patients with PE were included. At the predefined interim analysis of 525 patients (50%
of the planned population), the 3 month rate of symptomatic or fatal recurrent VTE was 0.6% (one-sided
upper 99.6% CI 2.1%), permitting the early rejection of the null hypothesis and termination of the trial.
Major bleeding occurred in six (1.2%) of the patients in the safety population. There were no PE-related
deaths [319]. In view of the existing evidence—and taking into consideration (i) the catastrophic scenario of
early death if a patient with acute PE is falsely judged to be at low risk on clinical grounds alone and
discharged “too early” (as described in a prematurely terminated trial [328]), and (ii) the ease and minimal
additional effort of assessing RV size and function at presentation by echocardiography, or on the CTPA
performed to diagnose the PE event itself [329] (section 5)—it is wise to exclude RV dysfunction and right
heart thrombi if immediate or early (within the first 24–48 h) discharge of the patient is planned.
8. Chronic treatment and prevention of recurrence
The aim of anticoagulation after acute PE is to complete the treatment of the acute episode and prevent
recurrence of VTE over the long-term. Current drugs and regimens for the initial phase, and the first
months of anticoagulant treatment, are described in section 6.
Most of the randomized studies focusing on long-term anticoagulation for VTE have included patients
with DVT, with or without PE; only two randomized studies have specifically focused on patients with PE
[330, 331]. The incidence of recurrent VTE does not appear to depend on the clinical manifestation of the
first event (i.e. it is similar after PE and after proximal DVT). However, in patients who have had a PE,
VTE more frequently recurs as PE, while in patients who have had a DVT, it tends to recur more
frequently as DVT [332]. As a consequence, the case fatality rate of recurrent VTE in patients who have
previously had a PE is twice as high as that of VTE recurrence after DVT [333, 334].
Landmark clinical trials have evaluated various durations of anticoagulant treatment with VKAs for VTE
[330, 331, 335–337]. The findings of these studies permit the following conclusions. First, all patients with PE
should receive ⩾3 months of anticoagulant treatment. Second, after withdrawal of anticoagulant treatment, the
risk of recurrence is expected to be similar if anticoagulants are stopped after 3–6 months compared with
longer treatment periods (e.g. 12–24 months). Third, extended oral anticoagulant treatment reduces the risk
for recurrent VTE by ⩽90%, but this benefit is partially offset by the risk of bleeding.
Oral anticoagulants are highly effective in preventing recurrent VTE during treatment, but they do not
eliminate the risk of subsequent recurrence after the discontinuation of treatment [330, 331]. Based on this fact
on the one hand, and considering the bleeding risk of anticoagulation treatment on the other, the clinically
important question is how to best select candidates for extended or indefinite anticoagulation. Involvement of
the patient in the decision-making process is crucial to optimize and maintain treatment adherence.
8.1. Assessment of venous thromboembolism recurrence risk
The risk for recurrent VTE after discontinuation of treatment is related to the features of the index PE (or,
in the broader sense, VTE) event. A study, which followed patients after a first episode of acute PE,
found that the recurrence rate after discontinuation of treatment was ∼2.5% per year after PE associated
with transient risk factors, compared with 4.5% per year after PE occurring in the absence of
known cancer, known thrombophilia, or any transient risk factor [331]. Similar observations were made in
other prospective studies in patients with DVT [337]. Advancing the concept further, randomized
anticoagulation trials over the past 15 years, which have focused on secondary VTE prevention, have
classified patients into distinct groups based on their risk of VTE recurrence after discontinuation
of anticoagulant treatment. In general, these groups are: (i) patients in whom a strong (major) transient or
reversible risk factor, most commonly major surgery or trauma, can be identified as being responsible
for the acute (index) episode; (ii) patients in whom the index episode might be partly explained by the
presence of a weak (minor) transient or reversible risk factor, or if a non-malignant risk factor for
thrombosis persists; (iii) patients in whom the index episode occurred in the absence of any identifiable
risk factor (the present Guidelines avoid terms such as “unprovoked” or “idiopathic” VTE); (iv) patients
with one or more previous episodes of VTE, and those with a major persistent pro-thrombotic condition
such as antiphospholipid antibody syndrome; and (v) patients with active cancer [338].
https://doi.org/10.1183/13993003.01647-2019 35
ACUTE PULMONARY EMBOLISM | S.V. KONSTANTINIDES ET AL.
Table 11 shows examples of transient/reversible and persistent risk factors for VTE, classified by the risk
of long-term recurrence. As active cancer is a major risk factor for recurrence of VTE, but also for
bleeding while on anticoagulant treatment [339], section 8.4 is specifically dedicated to the management of
PE in patients with cancer.
Overall, assessment of the VTE recurrence risk after acute PE, in the absence of a major transient or
reversible risk factor, is a complex issue. Beyond the examples listed in table 11, patients who are carriers
of some forms of hereditary thrombophilia, notably those with confirmed deficiency of antithrombin,
protein C, or protein S, and patients with homozygous factor V Leiden or homozygous prothrombin
G20210A mutation, are often candidates for indefinite anticoagulant treatment after a first episode of PE
occurring in the absence of a major reversible risk factor. In view of these possible implications, testing for
thrombophilia (including antiphospholipid antibodies and lupus anticoagulant) [342] may be considered
in patients in whom VTE occurs at a young age (e.g. aged <50 years) and in the absence of an otherwise
identifiable risk factor, especially when this occurs against the background of a strong family history of
VTE. In such cases, testing may help to tailor the regimen and dose of the anticoagulant agent over the
long-term. On the other hand, no evidence of a clinical benefit of extended anticoagulant treatment is
currently available for carriers of heterozygous factor V Leiden or prothrombin 20210A mutation.
A number of risk prediction models have been developed for the assessment of the risk of recurrence in an
individual patient (supplementary table 13) [343, 344]. The clinical value and, in particular, the possible
therapeutic implications of these models in the NOAC era are unclear.
8.2. Anticoagulant-related bleeding risk
Incidence estimates from cohort studies conducted more than 15 years ago reported an ∼3% annual
incidence of major bleeding in patients treated with VKAs [345]. Meta-analyses of phase III studies
TABLE 11 Categorization of risk factors for venous thromboembolism based on the risk of recurrence over the long-term
Estimated risk for long-term recurrencea Risk factor category for index PEb Examplesb
Low (<3% per year)
Major transient or reversible factors associated 
with >10-fold increased risk for the index VTE 
event (compared to patients without the risk 
factor)
•  Surgery with general anaesthesia for 
>30 min
•  Confined to bed in hospital (only “bathroom 
privileges”) for ≥3 days due to an acute 
illness, or acute exacerbation of a chronic 
illness
•  Trauma with fractures
Intermediate (3-8% per year)
Transient or reversible factors associated with 
≤10-fold increased risk for first (index) VTE
•  Minor surgery (general anaesthesia for 
<30 min)
•  Admission to hospital for <3 days with an 
acute illness
•  Oestrogen therapy/contraception
•  Pregnancy or puerpium
•  Confined to bed out of hospital for ≥3 days 
with an acute illness
•  Leg injury (without fracture) associated with 
reduced mobility ≥3 days
•  Long-haul flight
High (>8% per year) •  Active cancer
•  One or more previous episodes of VTE in the 
absence of a major transient or reversible 
factor
•  Antiphospholipid antibody syndrome
Non-malignant persistent risk factors •  Inflammatory bowel disease
•  Active autoimmune disease
No identifiable risk factor
PE: pulmonary embolism; VTE: venous thromboembolism. aIf anticoagulation is discontinued after the first 3 months (based on data from Baglin
et al. [340] and Iorio et al. [341]). bThe categorization of risk factors for the index VTE event is in line with that proposed by the International
Society on Thrombosis and Haemostasis [338]. The present Guidelines avoid terms such as “provoked”, “unprovoked”, or “idiopathic” VTE.
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focusing on the first 3–12 months of anticoagulant treatment showed an ∼40% reduction in the risk for
major bleeding with NOACs compared with VKAs [346]. The risk of major bleeding is higher in the first
month of anticoagulant treatment, and then declines and remains stable over time. Based on currently
available evidence, risk factors include: (i) advanced age (particularly >75 years); (ii) previous bleeding
(if not associated with a reversible or treatable cause) or anaemia; (iii) active cancer; (iv) previous stroke,
either haemorrhagic or ischaemic; (v) chronic renal or hepatic disease; (vi) concomitant antiplatelet
therapy or non-steroidal anti-inflammatory drugs (to be avoided, if possible); (vii) other serious acute or
chronic illness; and (viii) poor anticoagulation control.
Existing bleeding risk scores and their current validation status are reviewed in supplementary table 14.
The patient’s bleeding risk should be assessed, either by implicit judgement after evaluating individual risk
factors or by the use of a bleeding risk score, at the time of initiation of anticoagulant treatment. It should
be reassessed periodically (e.g. once a year in patients at low risk, and every 3 or 6 months in patients at
high risk for bleeding). Bleeding risk assessment should be used to identify and treat modifiable bleeding
risk factors, and it may influence decision-making on the duration and regimen/dose of anticoagulant
treatment after acute PE.
8.3. Regimens and treatment durations with non-vitamin K antagonist oral anticoagulants, and
with other non-vitamin K antagonist antithrombotic drugs
All patients with PE should be treated with anticoagulants for ⩾3 months [347]. Beyond this period, the
balance between the risk of VTE recurrence and that of bleeding, which has been used to select
candidates for extended anticoagulation after a first VTE event in the VKA era, is currently being revisited
based on the lower bleeding rates with NOACs. However, despite the improved safety of these drugs
compared with VKAs, treatment with NOACs is not without risk. Phase III clinical trials on the extended
treatment of VTE have shown that the rate of major bleeding may be ∼1%, and that of clinically relevant
non-major (CRNM) bleeding as high as 6%. Bleeding rates may be higher in everyday clinical practice
[348, 349].
The NOAC trials that focused on extended VTE treatment are summarized in supplementary table 15. In
all studies, patients with PE made up approximately one-third of the entire study population, while the
remaining two-thirds were patients with proximal DVT but no clinically overt PE. Patients needed to have
completed the initial and long-term anticoagulation phase to be included in the extended studies.
Dabigatran was compared with warfarin or placebo in two different studies (supplementary table 15)
[350]. In these studies, dabigatran was non-inferior to warfarin for the prevention of confirmed recurrent
symptomatic VTE or VTE-related death, and more effective than placebo for the prevention of
symptomatic recurrent VTE or unexplained death [350]. The rate of major bleeding was 0.9% with
dabigatran compared to 1.8% with warfarin (HR 0.52, 95% CI 0.27–1.02) [350].
Rivaroxaban was compared with placebo or aspirin in two different studies in patients who had completed
6–12 months of anticoagulation treatment for a first VTE event (supplementary table 15). Treatment with
rivaroxaban [20 mg once a day (o.d.)] reduced recurrent VTE by ∼80%, with a 6.0% incidence of major or
CRNM bleeding as compared to 1.2% with placebo [351]. Rivaroxaban given at a dose of 20 or 10 mg o.d.
was compared with aspirin (100 mg o.d.) in 3365 patients [352]. Both doses of rivaroxaban reduced
symptomatic recurrent fatal or non-fatal VTE by ∼70% in comparison with aspirin. No significant differences
in the rates of major or CRNM bleeding were shown between either dose of rivaroxaban and aspirin [352].
Patients with VTE were randomized to receive two different doses of apixaban [2.5 or 5 mg twice a day
(bis in die: b.i.d.)] or placebo after 6–12 months of initial anticoagulation (supplementary table 15) [353].
Both doses of apixaban reduced the incidence of symptomatic recurrent VTE or death from any cause
compared with placebo, with no safety concerns [353].
Patients at high bleeding risk—based on the investigator’s judgement, the patient’s medical history, and
the results of laboratory examinations—were excluded from the extension studies mentioned above; this
was also the case for studies on extended anticoagulation with VKAs [330, 331]. This fact should be taken
into account during triage of a patient for extended anticoagulation with one of the above regimens.
In a randomized, open-label study in high-risk patients with antiphospholipid syndrome (testing triple
positive for lupus anticoagulant, anticardiolipin, and anti-β2-glycoprotein I), rivaroxaban was associated
with an increased rate of thromboembolic and major bleeding events compared with warfarin (HR for the
composite primary outcome 6.7; 95% CI 1.5–30.5) [354]. At present, NOACs are not an alternative to
VKAs for patients with antiphospholipid syndrome.
In two trials with a total of 1224 patients, extended therapy with aspirin (after termination of standard
oral anticoagulation) was associated with a 30–35% reduction in the risk of recurrence compared with
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placebo (supplementary table 15) [355, 356]. However, more recently, another trial demonstrated the
superiority of anticoagulation with rivaroxaban, either 20 or 10 mg o.d., over aspirin for secondary
prophylaxis of VTE recurrence [352].
A randomized, placebo controlled study evaluated sulodexide (2×250 lipasemic unit capsules b.i.d.) for the
prevention of recurrence in 615 patients with a first VTE event without an identifiable risk factor, who
had completed 3–12 months of oral anticoagulant treatment (supplementary table 15) [357]. Sulodexide
reduced the risk of recurrence by ∼50% with no apparent increase in bleeding events. However, only 8%
of patients in this study had PE as the index VTE event [357].
8.4. Recommendations for the regimen and duration of anticoagulation after pulmonary
embolism in patients without cancer
Recommendations Classa Levelb
Therapeutic anticoagulation for ≥ 3 months is recommended for all patients with PE [347]. AI
Patients in whom discontinuation of anticoagulation after 3 months is recommended 
For patients with first PE/VTE secondary to a major transient/reversible risk factor, 




Patients in whom extension of anticoagulation beyond 3 months is recommended 
Oral anticoagulant treatment of indefinite duration is recommended for patients presenting 
with recurrent VTE (that is, with at least one previous episode of PE or DVT) not related to a 
major transient or reversible risk factor [358]. 
BI
Oral anticoagulant treatment with a VKA for an indefinite period is recommended for 
patients with antiphospholipid antibody syndrome [359].
AIIa
Patients in whom extension of anticoagulation beyond 3 months should be consideredc,d 
Extended oral anticoagulation of indefinite duration should be considered for patients with a 
first episode of PE and no identifiable risk factor [330, 331, 347, 351–353].
AIIa
NOAC dose in extended anticoagulatione 
If extended oral anticoagulation is decided after PE in a patient without cancer, a reduced 
dose of the NOACs apixaban (2.5 mg b.i.d.) or rivaroxaban (10 mg o.d.) should be considered 
after 6 months of therapeutic anticoagulation [352, 353].
CIIa
Extended oral anticoagulation of indefinite duration should be considered for patients with a 
first episode of PE associated with a persistent risk factor other than antiphospholipid 
antibody syndrome [330, 352, 353].
CIIa
Extended oral anticoagulation of indefinite duration should be considered for patients with a 
first episode of PE associated with a minor transient or reversible risk factor [330, 331, 352].
BIIb
Extended treatment with alternative antithrombotic agents 
In patients who refuse to take or are unable to tolerate any form of oral anticoagulants, 
aspirin or sulodexide may be considered for extended VTE prophylaxis [355–357].
CI
Follow-up of the patient under anticoagulation 
In patients who receive extended anticoagulation, it is recommended that their drug 
tolerance and adherence, hepatic and renalf function, and bleeding risk be reassessed at 
regular intervals [259].
b.i.d.: bis in die (twice a day); DVT: deep vein thrombosis; NOAC(s): non-vitamin K antagonist oral
anticoagulant(s); o.d.: omni die (once a day); PE: pulmonary embolism; VKA: vitamin K antagonist; VTE:
venous thromboembolism. aClass of recommendation. bLevel of evidence. cThe patient’s bleeding risk
should be assessed (see supplementary table 14 for prediction models) to identify and treat modifiable
bleeding risk factors, and it may influence decision-making on the duration and regimen/dose of
anticoagulant treatment. dRefer to supplementary table 9 for therapeutic decisions in specific clinical
situations. eIf dabigatran or edoxaban is chosen for extended anticoagulation after PE, the dose should
remain unchanged, as reduced-dose regimens were not investigated in dedicated extension trials [313,
350]. fEspecially for patients receiving NOACs.
8.5. Management of pulmonary embolism in patients with cancer
Five RCTs compared LMWH versus conventional VTE treatment (heparin followed by VKA) in the
treatment of VTE in cancer-associated thrombosis [360–364]. In 2003, a significant reduction in VTE
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recurrence was reported with LMWH compared with conventional (VKA) treatment without an increase
in bleeding complications [362]. In a more recent trial, long-term administration of tinzaparin failed to
achieve a statistically significant reduction in overall VTE recurrence over conventional treatment (HR
0.65, 95% CI 0.41–1.03); however, the overall rate of recurrent VTE in the control arm was lower than that
previously observed, probably as a result of the recruitment of patients with a lower cancer-specific
thrombotic risk [360]. Overall, LMWHs were found to decrease the risk of recurrent VTE by 40% with a
risk of major bleeding complications similar to that of VKAs [365]. Accordingly, LMWHs have become
the standard of care. However, these agents are associated with a relevant cost and burden for patients. In
addition, the absolute rate of recurrent VTE while on LMWH remains high (7–9%) compared with that
observed in non-cancer patients with VTE on conventional treatment (1.5–3%) [365].
NOACs could make the treatment of VTE easier and more convenient in patients with cancer, due to their
oral administration in fixed-dose regimens and their lower cost compared with LMWH. However, only
3–9% of patients included in phase III studies with NOACs for the treatment of VTE had concomitant
cancer [260, 261, 312, 314, 351]. A randomized, open-label trial compared edoxaban with LMWH in the
secondary prevention of VTE in 1050 patients with cancer-associated thrombosis (mostly symptomatic or
asymptomatic PE) [366]. Edoxaban (60 mg o.d., reduced to 30 mg in subjects with moderate renal
impairment, low body weight, or concomitant need for strong inhibitors of glycoprotein-P) was started
after 5 days of LMWH and treatment was given for ⩾6 months. Edoxaban was non-inferior to dalteparin
in the prevention of VTE recurrence or major bleeding over 12 months after randomization (HR 0.97,
95% CI 0.70–1.36). Major bleeding occurred in 6.9% of the patients in the edoxaban arm and 4.0% in the
dalteparin arm (difference in risk 2.9 percentage points, 95% CI 0.1–5.6). This difference appears to have
been mainly accounted for by the high rate of bleeding in patients with gastrointestinal cancer allocated to
the edoxaban group [366]. Similar results were reported by a randomized, open-label pilot trial comparing
rivaroxaban with dalteparin in 406 patients with VTE and cancer, 58% of whom had metastases [367].
A significant decrease in the risk of recurrent VTE was observed with rivaroxaban (HR 0.43, 95% CI
0.19–0.99). The 6 month cumulative rate of major bleeding, which was mostly gastrointestinal, was 6%
(95% CI 3–11%) for rivaroxaban and 4% (95% CI 2–8%) for dalteparin (HR 1.83, 95% CI 0.68–4.96).
Corresponding rates of CRNM bleeds were 13% (95% CI 9–19%) and 4% (95% CI 2–9%), respectively
(HR 3.76, 95% CI 1.63–8.69) [367].
Based on the currently available evidence, as described above, patients with acute PE and cancer,
particularly those with gastrointestinal cancer, should be encouraged to continue LMWH for
⩾3–6 months. This also applies to patients in whom oral treatment is unfeasible due to problems of intake
or absorption, and to those with severe renal impairment. In all other cases, especially in patients with an
anticipated low risk of bleeding and without gastrointestinal tumours, the choice between LMWH and
edoxaban or rivaroxaban is left to the discretion of the physician, and the patient’s preference.
Owing to the high risk for recurrence, patients with cancer should receive indefinite anticoagulation after a
first episode of VTE. Although existing evidence is limited, it is conceivable that once cancer is cured the
risk for recurrence decreases and anticoagulation can be stopped. However, the definition of cured cancer
is not always clear. The risk of recurrence of PE in cancer was assessed in a cohort study of 543 patients
and was validated in an independent set of 819 patients [368]. The proposed score to predict the risk of
recurrence included breast cancer (minus 1 point), Tumour Node Metastasis stage I or II (minus 1 point),
and female sex, lung cancer, and previous VTE (plus 1 point each). Patients with a score ⩽0 were at low
risk (⩽4.5%) and those with a score ⩾1 were at high (⩾19%) risk of VTE recurrence over the first
6 months [368].
After the first 3–6 months, extended anticoagulation may consist of continuation of LMWH or transition
to an oral anticoagulant. Two cohort studies have assessed the safety of extended treatment with LMWH
(⩽12 months) in cancer-associated thrombosis [369, 370]. In both studies, the incidence of bleeding
complications was higher in the first months and then reached a plateau that remained unchanged after
the sixth month. In the absence of conclusive evidence, the decision to continue with LMWH or to
change to VKA or a NOAC should be made on a case-by-case basis after consideration of the success of
anticancer therapy, the estimated risk of recurrence of VTE, the bleeding risk, and the preference of the
patient. Periodic reassessment of the risk-to-benefit ratio of continued anticoagulant treatment is
mandatory.
As mentioned in section 5, venous filters are principally indicated when anticoagulation is impossible due
to active haemorrhage or an excessive bleeding risk. However, the risk of VTE recurrence in the absence of
anticoagulation is particularly high in patients with cancer, and the insertion of a filter should not delay
the initiation of anticoagulation as soon as it is safe to do so. There is no evidence to support the use of
venous filters as an adjunct to anticoagulation treatment in patients with cancer.
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A number of studies have reported that a proportion of patients presenting with PE in the absence of
identifiable risk factors develop cancer within the first year after diagnosis [371]. Consequently, the
optimal strategy to achieve early diagnosis of these occult cancers was investigated. Two large randomized
trials failed to show that comprehensive CT of the abdomen or 18F deoxy-fluoro-glucose positron emission
tomography were able to detect more cancers than limited screening in patients with an unprovoked VTE
[372, 373]. Therefore, based on current evidence, the search for occult cancer after an episode of VTE may
be restricted to careful history taking, physical examination, basic laboratory tests, and a chest X-ray (if no
CTPA was performed to diagnose PE) [372, 374, 375].
In patients with cancer, incidental PE should be managed in the same manner as symptomatic PE,
whether it involves segmental or more proximal branches, multiple subsegmental vessels, or a single
subsegmental vessel in association with detectable DVT [376, 377].
8.6. Recommendations for the regimen and the duration of anticoagulation after pulmonary
embolism in patients with active cancer
Recommendations Classa Levelb
For patients with PE and cancer, weight-adjusted subcutaneous LMWH should be 
considered for the first 6 months over VKAs [360–363]. AIIa
Edoxaban should be considered as an alternative to weight-adjusted subcutaneous LMWH 
in patients without gastrointestinal cancer [366]. BIIa
Rivaroxaban should be considered as an alternative to weight-adjusted subcutaneous 
LMWH in patients without gastrointestinal cancer [367]. CIIa
For patients with PE and cancer, extended anticoagulation (beyond the first 6 months)c 
should be considered for an indefinite period or until the cancer is cured [378]. BIIa
In patients with cancer, management of incidental PE in the same manner as symptomatic 
PE should be considered, if it involves segmental or more proximal branches, multiple 
subsegmental vessels, or a single subsegmental vessel in association with proven 
DVT [376, 377].
BIIa
DVT: deep vein thrombosis; LMWH: low-molecular weight heparin; PE: pulmonary embolism; VKAs:
vitamin K antagonists. aClass of recommendation. bLevel of evidence. cRefer to supplementary table 9 for
further guidance on therapeutic decisions after the first 6 months.
9. Pulmonary embolism and pregnancy
9.1. Epidemiology and risk factors for pulmonary embolism in pregnancy
Acute PE remains one of the leading causes of maternal death in high-income countries [379, 380]. For
example, in the UK and Ireland, thrombosis and thromboembolism were the most common causes of
direct maternal death (death resulting from the pregnancy rather than pre-existing conditions) in the
triennium 2013–15, resulting in 1.13 mortalities per 100000 maternities (www.npeu.ox.ac.uk/mbrrace-uk).
VTE risk is higher in pregnant women compared with non-pregnant women of similar age; it increases
during pregnancy and reaches a peak during the post-partum period [381]. The baseline pregnancy-related
risk increases further in the presence of additional VTE risk factors, including in vitro fertilization: in a
cross-sectional study derived from a Swedish registry, the HR for VTE following in vitro fertilization was 1.77
(95% CI 1.41–2.23) overall and 4.22 (95% CI 2.46–7.20) during the first trimester [382]. Other important and
common risk factors include prior VTE, obesity, medical comorbidities, stillbirth, pre-eclampsia, post-partum
haemorrhage, and caesarean section; documented risk assessment is therefore essential [383].
The recommendations provided in these Guidelines are in line with those included in the 2018 ESC
Guidelines on the management of cardiovascular diseases during pregnancy [384].
9.2. Diagnosis of pulmonary embolism in pregnancy
9.2.1. Clinical prediction rules and D-dimers
Diagnosis of PE during pregnancy can be challenging as symptoms frequently overlap with those of
normal pregnancy. The overall prevalence of confirmed PE is low among women investigated for the
disease, between 2 and 7% [385–388]. D-dimer levels continuously increase during pregnancy [389, 390],
and levels are above the threshold for VTE “rule-out” in almost one-quarter of pregnant women in the
third trimester [390]. The results of a multinational prospective management study of 441 pregnant
women presenting to emergency departments with clinically suspected PE suggest that a diagnostic
strategy–based on the assessment of clinical probability, D-dimer measurement, CUS, and CTPA–may
safely exclude PE in pregnancy [388]. In that study, PE exclusion on the basis of a negative D-dimer result
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(without imaging) was possible in 11.7% of the 392 women with a non-high pre-test probability (Geneva)
score, a rate that was reduced to 4.2% in the third trimester [388]. A further prospective management
study evaluated a combination of a pregnancy-adapted YEARS algorithm with D-dimer levels in 498
women with suspected PE during pregnancy. PE was ruled out without CTPA in women deemed to be at
low PE risk according to the combination of the algorithm and D-dimer results. At 3 months, only one
woman with PE excluded on the basis of the algorithm developed a popliteal DVT (0.21%, 95% CI 0.04–1.2)
and no women developed PE [391].
9.2.2. Imaging tests
A proposed algorithm for the investigation of suspected PE in women who are pregnant, or ⩽6 weeks
post-partum, is shown in figure 7. Both maternal and fetal radiation exposure are low using modern
imaging techniques (table 12) [385, 392–398]. For V/Q scans and CTPA, fetal radiation doses are well
below the threshold associated with fetal radiation complications (which is 50–100 mSv) [399, 400]. In the
past, CTPA has been reported to cause high radiation exposure to the breast [395, 401]; however, CT
technology has evolved, and several techniques can now reduce radiation exposure without compromising
image quality. These include reducing the anatomical coverage of the scan [393], reducing the kilovoltage,
using iterative reconstructive techniques, and reducing the contrast-monitoring component of the CTPA
[392, 393]. Modern CTPA imaging techniques may therefore expose the maternal breast to median doses
as low as 3–4 mGy (table 12) [392]. The effect on maternal cancer risk with modern CTPA techniques is
negligible (lifetime cancer risk is reportedly increased by a factor of 1.0003–1.0007); avoiding CTPA on the
grounds of maternal cancer risk is therefore not justified [394].
Negative Indeterminate or positive
Proximal DVT not present 
SUSPECTED PE DURING PREGNANCY
High pretest probability, or intermediate/low
probability and positive D-dimer result
Anticoagulate with LMWH
SPECIFIC INVESTIGATION FOR PE
• If chest X-ray normal     CTPA or perfusion lung scan
• If chest X-ray abnormala       CTPAc
• Chest X-raya
• Compression proximal duplex ultrasound,
if symptoms or signs suggestive of DVTb
Review by radiologist or
nuclear physician
experienced in diagnosis






• Continue with LMWH at therapeutic dosed 
• Assess PE severity and the risk of early death e
• Refer to multidisciplinary team with experience of PE management in pregnancy
• Provide plan to guide management of pregnancy, labour and delivery, postnatal and future care 
FIGURE 7 Diagnostic workup and management of suspected pulmonary embolism during pregnancy, and up
to 6 weeks post-partum. CTPA: computed tomography pulmonary angiography; CUS: compression
ultrasonography; DVT: deep vein thrombosis; LMWH: low-molecular-weight heparin; PE: pulmonary embolism.
aIf chest X-ray abnormal, consider also alternative cause of chest symptoms. bDVT in pelvic veins may not be
ruled out by CUS. If the entire leg is swollen, or there is buttock pain or other symptoms suggestive of pelvic
thrombosis, consider magnetic resonance venography to rule out DVT. cCTPA technique must ensure very low
fetal radiation exposure (see table 12). dPerform full blood count (to measure haemoglobin and platelet
count) and calculate creatinine clearance before administration. Assess bleeding risk and ensure absence of
contra-indications. eSee table 8.
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A normal perfusion scan and a negative CTPA appear equally safe for ruling out PE in pregnancy, as
suggested by retrospective series [385, 386, 402–404]. Inconclusive results can be a problem (4–33% of
investigations) [385, 386, 405], especially late in pregnancy [405]. A recent survey of 24 sites in the UK,
representing a population of 15.5 million, revealed a similar rate of inadequate or indeterminate CTPA
and scintigraphy scans, suggesting that the initial choice of imaging is best determined by local expertise
and resources [406].
V/Q SPECT is associated with low fetal and maternal radiation exposure, and has promise in PE diagnosis
in pregnancy [407]. However, further evaluation of this technique is required before its widespread
incorporation into diagnostic algorithms. For MRA, the long-term effects of gadolinium contrast on the
fetus are not known. In non-pregnant patients, technically inadequate images are frequently obtained and
the rate of inconclusive scan results is high [140]. Therefore, use of this technique for diagnosing or ruling
out PE during pregnancy cannot be recommended at present. Conventional pulmonary angiography
involves significantly higher radiation exposure of the fetus (2.2–3.7 mSv) and should be avoided during
pregnancy [400].
Overdiagnosis of PE is a potential pitfall that can have significant, lifelong implications for a pregnant
woman, including the risk of bleeding at the time of delivery, the withholding of oestrogen contraception,
and the requirement for thromboprophylaxis during future pregnancies. Consequently, avoiding PE
overdiagnosis in pregnancy is as important as not missing a PE diagnosis.
9.3. Treatment of pulmonary embolism in pregnancy
LMWH is the treatment of choice for PE during pregnancy [384]. In contrast to VKAs and NOACs,
LMWH does not cross the placenta, and consequently does not confer a risk of fetal haemorrhage or
teratogenicity. Moreover, while UFH is also safe in pregnancy, LMWH has more predictable
pharmacokinetics and a more favourable risk profile [408–411]. Although no RCT has evaluated the
optimal dose of LMWH for the treatment of PE during pregnancy, currently published data favour similar
dosing to non-pregnant patients, either with o.d. or b.i.d. regimens based on early pregnancy weight [408,
410]. For the majority of patients receiving LMWH treatment for PE during pregnancy [412, 413], it
remains uncertain whether using serial measurements of plasma anti-activated coagulation factor X
activity to guide dosing may be of clinical benefit. It is important to bear in mind that: (i) LMWH has a
predictable pharmacokinetic profile, (ii) data on optimal anti-activated coagulation factor levels are lacking,
and (iii) the assay itself has limitations [414]. In addition, there are no solid data on the clinical benefit
versus harm of frequent, weight-based dose adjustments of LMWH during pregnancy. Thus, anti-activated
coagulation factor X monitoring may be reserved for specific high-risk circumstances such as recurrent
VTE, renal impairment, and extremes of body weight.
The use of UFH has been associated with heparin-induced thrombocytopenia and bone loss. It remains
uncertain whether, and to what extent, the risk of bone loss is increased with LMWH use. In a recent
observational cohort study, in which bone mineral density was measured by dual-energy X-ray
absorptiometry 4–7 years after the last delivery in 152 women (92 of whom received prolonged LMWH
during pregnancy), lumbar spine bone mineral density was similar in LWMH-treated women and
TABLE 12 Estimated amounts of radiation absorbed in procedures used to diagnose pulmonary
embolism (based on various references [385, 392–398])
Test Estimated fetal radiation
exposure (mGy)a
Estimated maternal radiation
exposure to breast tissue (mGy)a
Chest X-ray <0.01 <0.1
Perfusion lung scan with
technetium-99m-labelled albumin
Low dose: ∼40 MBq 0.02–0.20 0.16–0.5
High dose: ∼200 MBq 0.20–0.60 1.2
Ventilation lung scan 0.10–0.30 <0.01
CTPA 0.05–0.5 3–10
CTPA: computed tomography pulmonary angiography; mGy: milligray; MBq: megabecquerel; PE:
pulmonary embolism. aIn this section, absorbed radiation dose is expressed in mGy to reflect the radiation
exposure to single organs, or the fetus, as a result of various diagnostic techniques. Compare with table 6,
in which effective radiation dose is expressed in millisieverts to reflect the effective doses of all organs that
have been exposed.
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controls following adjustment for potential confounders. No osteoporosis or osteoporotic fractures were
reported [415].
Fondaparinux may be considered if there is an allergy or adverse response to LMWH, although solid data
are lacking and minor transplacental passage has been demonstrated [416]. VKAs cross the placenta and
are associated with a well-defined embryopathy during the first trimester. Administration of VKAs in the
third trimester can result in fetal and neonatal haemorrhage, as well as placental abruption. Warfarin may
be associated with central nervous system anomalies in the fetus throughout pregnancy. NOACs are
contraindicated in pregnant patients [417].
The management of labour and delivery requires particular attention. In women receiving therapeutic
LMWH, strong consideration should be given to planned delivery in collaboration with the
multidisciplinary team to avoid the risk of spontaneous labour while fully anticoagulated. The incidence of
spinal haematoma after regional anaesthesia is unknown in pregnant women under anticoagulation
treatment. If regional analgesia is considered for a woman receiving therapeutic LMWH, ⩾24 h should
have elapsed since the last LMWH dose before insertion of a spinal or epidural needle (assuming normal
renal function and including risk assessment at extremes of body weight).
In high-risk situations, for example in patients with recent PE, it is recommended that LMWH be
converted to UFH ⩾36 h prior to delivery. The UFH infusion should be stopped 4−6 h prior to
anticipated delivery and the activated partial thromboplastin time should be normal (i.e. not prolonged)
prior to regional anaesthesia [418].
Data are limited on the optimal timing of post-partum reinitiation of LMWH [419, 420]. Timing will
depend upon the mode of delivery and an assessment of the thrombotic versus bleeding risk by a
multidisciplinary team. LMWH should not be given for ⩾4 h after removal of the epidural catheter; the
decision on timing and dose should consider whether the epidural insertion was traumatic, and take into
account the risk profile of the woman. For example, an interim dose of a prophylactic LMWH dose may
be considered post-operatively (after caesarean section), once at least 4 h have elapsed since epidural
catheter removal, and allowing for an interval of ⩾8–12 h between the prophylactic and the next
therapeutic dose. Close collaboration between the obstetrician, the anaesthesiologist, and the attending
physician is recommended.
Anticoagulant treatment should be administered for ⩾6 weeks after delivery and with a minimum overall
treatment duration of 3 months. LMWH and warfarin can be given to breastfeeding mothers; the use of
NOACs is not recommended [417].
High-risk, life-threatening PE during pregnancy is a rare, but potentially devastating, event. A recent
systematic review included 127 cases of severe PE during pregnancy (and until 6 weeks post-partum)
treated with thrombolysis, thrombectomy, and/or ECMO [421]. Both high- and intermediate-risk PE cases
were included, and 23% of women experienced cardiac arrest. Reported survival rates were 94 and 86%
following thrombolysis and surgical thrombectomy, respectively; however, these favourable rates may
reflect reporting bias. Following thrombolysis, major bleeding occurred in 18 and 58% of cases during
pregnancy and in the post-partum period, respectively [421]. Finally, fetal deaths occurred in 12 and 20%
of the cases following thrombolysis and thrombectomy, respectively [421]. Thrombolytic treatment should
not be used peri-partum, except in the setting of life-threatening PE. Typically, UFH is used in the acute
treatment of high-risk PE.
Although the indications for vena cava filters are similar to those for non-pregnant patients (discussed in
section 6), there is limited experience with their use in pregnancy and the risk associated with the
procedure may be increased.
Suggestions for the anticoagulation management of PE in specific clinical situations (also) related to
pregnancy, for which conclusive evidence is lacking, are presented in supplementary table 9.
9.3.1. Role of a multidisciplinary pregnancy heart team
A team of multidisciplinary colleagues should collaborate in the planning of ante-, peri-, and post-partum
care pathways for women with cardiovascular diseases, including PE. As many members as possible of this
team should have expertise in the management of PE during pregnancy and the post-partum period.
Jointly agreed, written care pathways should be available (if timelines permit) for effective communication
(an example is shown in figure 7).
9.4. Amniotic fluid embolism
Amniotic fluid embolism (AFE) is a rare condition that occurs during pregnancy or shortly after delivery.
It remains one of the leading causes of direct maternal death (i.e. death resulting from the pregnancy
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rather than from pre-existing conditions) in high-income countries [422]. Diagnosis of AFE is challenging,
being primarily a clinical diagnosis of exclusion. Awareness of AFE, prompt diagnosis, and aggressive life
support are of critical importance. AFE is characterized by unexplained sudden cardiovascular or
respiratory deterioration, often accompanied by disseminated intravascular coagulation [422], and
occurring during pregnancy or after delivery [423, 424]. The reported incidence is approximately 2–7 per
100000 maternities, with a mortality rate of 0.5–6 deaths per 100000 deliveries [422, 425, 426]. Reported
case fatality rates vary, reflecting the challenges in making the diagnosis and the rarity of AFE. In a
retrospective Californian study including more than 3.5 million deliveries, a case fatality rate of 13% was
reported, as in other US and Canadian studies [425]. Similarly, a case fatality rate of 19% was reported in
a recent prospective UK population-based study with validated case criteria [422]. Recent literature have
suggested that risk factors for AFE may include pre-existing cardiac, cerebrovascular, and renal disorders,
placenta previa, polyhydramnios, stillbirth, chorioamnionitis, hypertensive disorders, instrumental delivery,
and caesarean section [422, 425]. Management of AFE is supportive, and based on high-quality emergency
care following the recognition and diagnosis of the condition, with prompt treatment of bleeding and
coagulopathy [423]. Awareness of AFE should be integral to the education of involved physicians and to
emergency algorithms.




Formal diagnostic assessment with validated methods is recommended if PE is suspected 
during pregnancy or in the post-partum period [388, 391]. BI
Treatment 
A therapeutic, fixed dose of LMWH based on early pregnancy body weight is the 
recommended therapy for PE in the majority of pregnant women without haemodynamic 
instability [408, 410].
BI
Amniotic fluid embolism 
Amniotic fluid embolism should be considered in a pregnant or post-partum woman with 
otherwise unexplained cardiac arrest, sustained hypotension, or respiratory deterioration, 
especially if accompanied by disseminated intravascular coagulation [422, 425, 426].
CIIa
Thrombolysis or surgical embolectomy should be considered for pregnant women with 
high-risk PE [421].
CIIa
Insertion of a spinal or epidural needle is not recommended, unless ≥24 h have passed 
since the last therapeutic dose of LMWH.
CIII
Administration of LMWH is not recommended within 4 h of removal of an epidural catheter. CIII
NOACs are not recommended during pregnancy or lactation. CIII
D-dimer measurement and clinical prediction rules should be considered to rule out PE 
during pregnancy or the post-partum period [388, 391]. BIIa
In a pregnant patient with suspected PE (particularly if she has symptoms of DVT), venous 
CUS should be considered to avoid unnecessary irradiation [388]. BIIa
Perfusion scintigraphy or CTPA (with a low-radiation dose protocol) should be considered to 
rule out suspected PE in pregnant women; CTPA should be considered as the first-line 
option if the chest X-ray is abnormal [385, 386].
CIIa
CTPA: computed tomography pulmonary angiography; CUS: compression ultrasonography; DVT: deep vein
thrombosis; LMWH: low-molecular weight heparin; NOACs: non-vitamin K antagonist oral anticoagulants;
PE: pulmonary embolism. aClass of recommendation. bLevel of evidence.
10. Long-term sequelae of pulmonary embolism
The patency of the pulmonary arterial bed is restored in the majority of PE survivors within the first few
months following the acute episode; therefore, no routine follow-up CTPA imaging is needed in such
patients treated for PE [427]. However, in other patients, thrombi become persistent and organized, which
in rare cases may result in CTEPH, a potentially life-threatening obstructing vasculopathy. The rarity of
this condition is in contrast to the relatively large number of patients who report persisting dyspnoea or
poor physical performance over several months after acute PE. Thus, the aims of an efficient follow-up
strategy after PE should be to: (i) provide appropriate care (exercise rehabilitation, treatment of
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comorbidity, behavioural education, and modification of risk factors) to patients with persisting symptoms,
and (ii) ensure early detection of CTEPH to refer the patient for further diagnostic workup and specific
treatment.
10.1. Persisting symptoms and functional limitation after pulmonary embolism
Cohort studies conducted over the past decade (summarized in Klok et al. [428]) have revealed that
persisting or deteriorating dyspnoea, and poor physical performance, are frequently present 6 months to
3 years after an acute PE episode. The proportion of patients claiming that their health status is worse at
6 month follow-up than it was at the time of PE diagnosis varies widely, ranging between 20 and 75%
[429–431]. The following baseline parameters and findings could be identified as predictors of exertional
dyspnoea at long-term follow-up after PE: advanced age, cardiac or pulmonary comorbidity, higher body
mass index, and history of smoking [429]; higher systolic PAP and RV dysfunction at diagnosis [430, 432,
433]; and residual pulmonary vascular obstruction at discharge [434].
More recently, a prospective cohort study enrolled 100 patients at five Canadian hospitals between 2010
and 2013, and followed them over 1 year [435]. As many as 47% of the patients had reduced maximal
aerobic capacity, defined as peak oxygen consumption <80% of the predicted value on cardiopulmonary
exercise testing (CPET). This functional outcome was associated with significantly worse generic
health-related quality of life and dyspnoea scores, as well as with a significantly reduced 6 min walk
distance [435]. Independent predictors of reduced functional exercise capacity and quality of life over time
included female sex, higher body mass index, history of lung disease, higher pulmonary artery systolic
pressures on the 10 day echocardiogram, and higher main pulmonary artery diameter on the baseline
CTPA [436]. Of note, pulmonary function tests and echocardiographic results at follow-up were largely
within normal limits, both in patients with and without reduced maximal aerobic capacity [435]. Lack of
an association between exercise impairment, and persistent RV dilation or dysfunction, was also reported
by a study of 20 survivors of massive or submassive PE [437].
Taken together, older and more recent cohort studies have suggested that muscle deconditioning,
particularly in the presence of excess body weight and cardiopulmonary comorbidity, is largely
responsible for the frequently reported dyspnoea and signs of exercise limitation after acute PE. This also
means that, at least in the majority of cases, poor physical performance after PE does not appear to be
attributable to “large” residual thrombi, or persisting/progressive PH and RV dysfunction. Ongoing
prospective studies in large numbers of patients may help to better identify predictors of functional and/or
haemodynamic impairment after acute PE, and their possible implications for shaping follow-up
programmes [438].
As mentioned in section 6, it remains unclear whether early reperfusion treatment, notably thrombolysis,
has an impact on clinical symptoms, functional limitation, or persistent (or new-onset) PH at long-term
follow-up after PE. Consequently, prevention of long-term PE sequelae is, at present, no justification for
thrombolytic treatment in the acute phase of PE.
10.2. Chronic thromboembolic pulmonary hypertension
10.2.1. Epidemiology, pathophysiology, and natural history
CTEPH is a disease caused by the persistent obstruction of pulmonary arteries by organized thrombi,
leading to flow redistribution and secondary remodelling of the pulmonary microvascular bed. CTEPH has
been reported with a cumulative incidence of between 0.1 and 9.1% in the first 2 years after a symptomatic
PE event; the large margin of error is due to referral bias, the paucity of early symptoms, and the difficulty
of differentiating acute PE from symptoms of pre-existing CTEPH [439, 440]. A prospective, multicentre,
observational screening survey for the detection of CTEPH included patients with acute PE from 11
centres in Switzerland, from March 2009 to November 2016. Screening for possible CTEPH was
performed at 6, 12, and 24 months using a stepwise algorithm that included a phone-based dyspnoea
survey, TTE, right heart catheterization, and radiological confirmation of CTEPH. Of 508 patients assessed
for CTEPH screening over 2 years, CTEPH incidence following PE was 3.7 per 1000 patient-years, with a
2 year cumulative incidence of 0.79% [441]. In Germany, the incidence of CTEPH in 2016 was estimated
at 5.7 per million adult population [442].
The hallmark of CTEPH is fibrotic transformation of a pulmonary arterial thrombus, causing fixed
mechanical obstruction of pulmonary arteries and leading to overflow of the open pulmonary arterial
bed. Together with collateral supply from systemic arteries downstream of pulmonary arterial
occlusions, this contributes to microvascular remodelling causing a progressive increase in PVR [443].
Owing to this complex pathophysiology, there is no clear correlation between the degree of mechanical
obstruction found at imaging and haemodynamics, which can deteriorate in the absence of recurrent
PE [444].
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Two historical trials assessed survival in patients with CTEPH before the availability of surgical treatment.
In both studies, mean PAP >30 mmHg was related to poor survival, similar to that reported for idiopathic
pulmonary arterial hypertension [445, 446].
The most frequently cited risk factors and predisposing conditions for CTEPH are shown in table 13. In
an international registry, a history of acute PE was reported by 75% of patients [447]. Associated
conditions and comorbidities included thrombophilic disorders, particularly antiphospholipid antibody
syndrome and high coagulation factor VIII levels, cancer, a history of splenectomy, inflammatory bowel
disease, ventriculo-atrial shunts, and infection of chronic i.v. lines and devices such as implantable
pacemakers.
10.2.2. Clinical presentation and diagnosis
Diagnosing CTEPH is difficult. Algorithms for predicting [450] or ruling out CTEPH [451, 452] are
limited by a lack of specificity. The clinical characteristics of patients enrolled in an international CTEPH
registry have shown that the median age at diagnosis is 63 years and that both sexes are equally affected;
paediatric cases are rare [447]. Clinical symptoms and signs are non-specific or absent in early CTEPH,
with signs of right heart failure only becoming evident in advanced disease. Thus, early diagnosis remains
a challenge in CTEPH, with a median time of 14 months between symptom onset and diagnosis in expert
centres [453]. When present, the clinical symptoms of CTEPH may resemble those of acute PE or of
pulmonary arterial hypertension; in the latter context, oedema and haemoptysis occur more often in
CTEPH, while syncope is more common in pulmonary arterial hypertension [453].
The diagnosis of CTEPH is based on findings obtained after at least 3 months of effective anticoagulation,
to distinguish this condition from acute PE. The diagnosis requires a mean PAP of ⩾25 mmHg along with
a pulmonary arterial wedge pressure of ⩽15 mmHg, documented at right heart catheterization in a patient
with mismatched perfusion defects on V/Q lung scan. Specific diagnostic signs for CTEPH on
multidetector CT angiography or conventional pulmonary cineangiography include ring-like stenoses,
webs, slits, and chronic total occlusions [289].
Some patients may present with normal pulmonary haemodynamics at rest despite symptomatic disease. If
other causes of exercise limitation are excluded, these patients are considered as having chronic
thromboembolic disease (CTED). Identification of patients with chronic thromboembolism without PH,
who may have an indication for surgical or interventional treatment, requires particular expertise and
should be done in CTEPH referral centres. Among 1019 patients who were submitted to pulmonary
endarterectomy (PEA) in a UK referral centre, 42 patients did not have pulmonary hypertension at rest
but showed functional improvement after the operation [454].
Planar V/Q lung scan is a suitable first-line imaging modality for CTEPH as it has 96–97% sensitivity and
90–95% specificity for the diagnosis [455]. SPECT seems less sensitive than planar V/Q scanning if
assessed at a level of individual segmental arteries, but it is unlikely to miss clinically relevant CTEPH in
an individual patient. In contrast to CTEPH, abnormal mismatched perfusion defects sometimes found in
TABLE 13 Risk factors and predisposing conditions for chronic thromboembolic pulmonary hypertension [447–449]
Findings related to the acute PE event (obtained at PE diagnosis) Concomitant chronic diseases and conditions predisposing
to CTEPH (documented at PE diagnosis or at 3–6 month follow-up)
Previous episodes of PE or DVT Ventriculo-atrial shunts
Large pulmonary arterial thrombi on CTPA Infected chronic i.v. lines or pacemakers
Echocardiographic signs of PH/RV dysfunctiona History of splenectomy
CTPA findings suggestive of pre-existing chronic
thromboembolic diseaseb
Thrombophilic disorders, particularly antiphospholipid antibody
syndrome and high coagulation factor VIII levels
Non-O blood group





CTEPH: chronic thromboembolic pulmonary hypertension; CTPA: computed tomographic pulmonary angiography; DVT: deep vein thrombosis; i.
v.: intravenous; LV: left ventricular; PE: pulmonary embolism; PH: pulmonary hypertension; RV: right ventricular. aEchocardiographic criteria of
RV dysfunction are graphically presented in Figure 3, and their prognostic value summarized in supplementary table 3. On CTPA
(four-chamber views of the heart), RV dysfunction is defined as RV/LV diameter ratio >1.0. bDirect and indirect vascular signs, as well as lung
parenchymal findings, are summarized in supplementary table 2.
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pulmonary arterial hypertension and pulmonary veno-occlusive disease typically have a non-segmental
pattern.
CTPA is gaining ground as a diagnostic modality in CTEPH [456], but it should not be used as a
stand-alone test to exclude the disease [455]. Newer diagnostic tests include dual-energy CT, which allows
the simultaneous assessment of patency of the pulmonary arteries and of lung perfusion, probably at a cost
of some increase in radiation delivered to the patient. Magnetic resonance imaging of the pulmonary
vasculature is still considered inferior to CT [457]. Cone-beam CT [458], angioscopy [459], intravascular
ultrasound, and optical coherence tomography are more suitable for the characterization of lesions during
interventional treatment than for diagnosis. High-resolution CT scan of the chest may assist in the
differential diagnosis of CTEPH, showing emphysema, bronchial, or interstitial lung disease, as well as
infarcts, and vascular and thoracic wall malformations. Perfusion inequalities manifesting as a mosaic
parenchymal pattern are frequently found in CTEPH, but may also be observed in ⩽12% of patients with
other causes of PH. Differential diagnosis of CTEPH should also include pulmonary arteritis, pulmonary
angiosarcoma, tumour embolism, parasites (hydatid cyst), foreign body embolism, and congenital or
acquired pulmonary artery stenoses [289].
10.2.3. Surgical treatment
Surgical PEA is the treatment of choice for operable CTEPH. In contrast to surgical embolectomy for
acute PE, treatment of CTEPH necessitates a true bilateral endarterectomy through the medial layer of the
pulmonary arteries. It requires deep hypothermia and intermittent circulatory arrest, without a need for
cerebral perfusion [460, 461]. In-hospital mortality is currently as low as 4.7% [462] and is even lower in
high-volume single centres [463]. The majority of patients experience substantial relief from symptoms
and near-normalization of haemodynamics [461–464]. Owing to the complexity of both the surgical
technique and peri-procedural management, PEA is performed in specialized centres. Eligibility for
surgery requires a decision taken during a dedicated meeting of a multidisciplinary CTEPH team
including experienced surgeons for PEA, interventional radiologists or cardiologists, radiologists
experienced in pulmonary vascular imaging, and clinicians with expertise in PH. The CTEPH team should
confirm the diagnosis, assess the surgical accessibility of chronic post-thrombotic obstructions (“surgical
operability”), and consider the risks related to comorbidities (“medical operability”). The operability of
patients with CTEPH is determined by multiple factors that cannot easily be standardized. These are
related to the suitability of the patient, the expertise of the surgical team, and available resources. General
criteria include pre-operative New York Heart Association (NYHA) functional class and the surgical
accessibility of thrombi in the main, lobar, or segmental pulmonary arteries [462]. Advanced age per se is
no contraindication for surgery. There is no haemodynamic threshold or measure of RV dysfunction that
can be considered to preclude PEA.
Data from the international CTEPH registry, set up in 27 centres to evaluate the long-term outcome and
outcome predictors in 679 operated and not-operated patients, showed estimated survival at 3 years of 89%
in operated and 70% in not-operated patients [465]. Mortality was associated with NYHA functional class,
RA pressure, and a history of cancer [465]. In this prospective registry, the long-term prognosis of
operated patients was better than the outcome of not-operated patients [465]. Additional correlates of
mortality were bridging therapy with pulmonary vasodilators, post-operative PH, surgical complications,
and additional cardiac procedures in operated patients, and comorbidities such as coronary disease, left
heart failure, and chronic obstructive pulmonary disease in not-operated patients [465]. A recent report
identified mean PAP ⩾38 mmHg and PVR ⩾425 dyn·s·cm−5 as determinants of poor prognosis in
survivors of surgical treatment for CTEPH [466].
Post-operative ECMO is recommended as the standard of care in PEA centres [461]. Early post-operative
reperfusion oedema may require veno-arterial ECMO, and severe persistent PH may be bridged to
emergency lung transplantation with ECMO. After PEA, patients should be followed in CTEPH centres to
exclude persistent or recurrent PH, with at least one haemodynamic assessment to be considered at
6–12 months after the intervention.
10.2.4. Balloon pulmonary angioplasty
Over the past decade, balloon pulmonary angioplasty (BPA) has emerged as an effective treatment for
technically inoperable CTEPH. It allows dilatation of obstructions down to subsegmental vessels, which are
inaccessible to surgery. BPA is a stepwise procedure requiring several (usually 4–10) separate sessions. This
is necessary to engage all under-perfused lung segments, while limiting the contrast burden and radiation
delivered per session. Navigation in distal pulmonary arteries requires particular expertise, as the
complexity and individual variability of the pulmonary arterial tree greatly exceeds that of other vascular
beds. Complications include wire- and balloon-induced injury, which may result in intrapulmonary
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bleeding, haemoptysis, and reperfusion lung injury. Usually, bleeding resolves spontaneously, but
sometimes it has to be controlled by transient balloon inflation proximal to the site of perforation; in rare
cases it requires embolization. Mild hypoxaemia is frequent and can be controlled by oxygen delivery.
Mechanical ventilation or ECMO is rarely needed.
The largest published registry to date included 249 patients with a mean age of 61.5 years, who were
treated with BPA between 2004 and 2013 in seven Japanese centres [467]. Mean PAP decreased from 43
to 24 mmHg after terminating BPA sessions, and this result was maintained in 196 patients who
underwent follow-up right heart catheterization. Complications occurred in 36% of the patients, including
pulmonary injury (18%), haemoptysis (14%), and pulmonary artery perforation (2.9%). After BPA, 30 day
mortality was 2.6% and overall survival was 97% at 1 year [467].
While most of the BPA procedures are performed in technically inoperable patients, this method has also
been used for sequential treatment for PH persisting after PEA. Few “rescue” BPA interventions performed
in unstable patients remaining on ECMO after PEA were ineffective [468].
10.2.5. Pharmacological treatment
Optimal medical treatment for CTEPH consists of anticoagulants, as well as diuretics and oxygen in cases
of heart failure or hypoxaemia. Lifelong oral anticoagulation with VKAs is recommended, and also after
successful PEA or BPA. No data exist on the efficacy and safety of NOACs.
Pulmonary microvascular disease in CTEPH has provided the rationale for also testing drugs that have
been approved for pulmonary arterial hypertension for this indication. Based on available data, medical
treatment of CTEPH with targeted therapy is now justified for technically inoperable patients [469, 470],
as well as for patients with PH persisting after PEA [469]. To date, the only drug approved for inoperable
CTEPH or persistent/recurrent PH after PEA is riociguat, an oral stimulator of soluble guanylate cyclase
[469]. In a prospective randomized trial of 261 patients with inoperable CTEPH or persistent/recurrent
PH after PEA, treatment with riociguat significantly increased 6 min walking distance and reduced PVR
[469]. In a similar population of 157 patients, the dual endothelin antagonist bosentan showed a positive
effect on haemodynamics, but no improvement was observed in exercise capacity and the primary
outcome was not met [471]. Another dual endothelin antagonist, macitentan, was found to significantly
improve PVR and 6 min walking distance compared to placebo in a phase II trial focusing on inoperable
patients with CTEPH [470]. Currently, riociguat is being tested in trials addressing its efficacy and safety:
(i) as bridging therapy for patients scheduled to undergo PEA (NCT 03273257) and (ii) in comparison to
BPA (NCT 02634203).
Overall, the effects on clinical worsening of drugs tested with RCTs in patients with CTEPH have not yet
been clarified. Furthermore, no data exist on medical treatment in technically operable patients with
prohibitive comorbidities or those refusing surgery. Off-label combination of drugs approved for
pulmonary arterial hypertension has been proposed for CTEPH patients presenting with severe
haemodynamic compromise, but only limited prospective data are available to date [470].
Medical therapy is not indicated in symptomatic survivors of acute PE with documented post-thrombotic
obstructions but an absence of PH at right heart catheterization at rest (CTED).
10.3. Strategies for patient follow-up after pulmonary embolism
Figure 8 displays a proposed follow-up strategy for survivors of acute PE following discharge from
hospital. Evaluation of the patients 3–6 months after the acute PE episode is recommended to assess the
persistence (or new onset) and severity of dyspnoea or functional limitation, and to check for possible
signs of VTE recurrence, cancer, or bleeding complications of anticoagulation. The severity of dyspnoea
can be assessed using the Medical Research Council scale [160]; alternatively, the World Health
Organization functional class can be determined (supplementary table 16) [289].
In patients complaining of persisting dyspnoea and poor physical performance, TTE should be considered
as the next step to assess the probability of (chronic) PH and thus possible CTEPH. The criteria and levels
of PH probability are defined by current ESC Guidelines [289], and are listed in supplementary tables 17
and 18. Patients with a high echocardiographic probability of PH, or those with intermediate probability
combined with elevated NT-proBNP levels or risk factors/predisposing conditions for CTEPH, such as
those listed in table 13, should be considered for a V/Q scan.
If mismatched perfusion defects are found on the V/Q scan, referral to a PH or CTEPH expert centre for
further diagnostic workup is indicated. If, on the other hand, the V/Q scan is normal and the patient’s
symptoms remain unexplained, CPET may be performed. By providing evidence of reduced maximal
aerobic capacity, CPET supports the need for further follow-up visits and helps to identify candidates for
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pulmonary rehabilitation, exercise, or weight-reduction programmes [435, 436]. CPET may also be helpful
in patients with suspected CTEPH and coexisting left heart and/or respiratory disease; in such cases, it can
help to establish the main limiting factor and thus set priorities for the treatment strategy [472].
For patients who report as free of dyspnoea or functional limitation at 3–6-month follow-up after acute PE
but have risk factors/predisposing conditions for CTEPH (table 13), further follow-up visits may be
scheduled and the patient must be advised to return if symptoms appear. Alternatively, TTE may be
considered to assess the probability of PH (figure 8).
Apart from the recommended screening and diagnostic measures, an integrated model of patient care after
PE should be provided, taking into consideration the infrastructure and possibilities offered by each
country’s health system. The model should include appropriately qualified nurses, interdisciplinary
working with physicians in the care of both in-hospital and ambulatory PE patients, standardized
treatment protocols adapted to the capacities of each hospital, and bidirectional referral pathways between
general practice and the hospital. Such models ensure smooth transitions between hospital specialists and
practitioners; provide continuity, and easy access to care along with information and education; and
respect the patients’ preferences, and those of their families and social environment. In this context,
DIAGNOSIS OF ACUTE PE
Refer to PH/CTEPH expert






Determine probability of PHc
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common causes of PH
Focus on anticoagulation
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FIGURE 8 Follow-up strategy and diagnostic workup for long-term sequelae of pulmonary embolism. CPET:
cardiopulmonary exercise testing; CTEPH: chronic thromboembolic pulmonary hypertension; NT-proBNP:
N-terminal pro B-type natriuretic peptide; PE: pulmonary embolism; PH: pulmonary hypertension; TTE:
transthoracic echocardiography/echocardiogram; V/Q: ventilation/perfusion (lung scintigraphy). aAssess the
persistence (or new onset) and severity of dyspnoea or functional limitation, and also check for possible signs
of VTE recurrence, cancer, or bleeding complications of anticoagulation. bThe Medical Research Council scale
can be used to standardize the evaluation of dyspnoea [160]; alternatively, the World Health Organization
functional class can be determined (supplementary table 16) [289]. cAs defined by the ESC/ERS guidelines on
the diagnosis and treatment of Pulmonary Hypertension (supplementary tables 17 and 18) [289]. dRisk factors
and predisposing conditions for CTEPH are listed in table 13. eCardiopulmonary exercise testing, if
appropriate expertise and resources are available on site; abnormal results include, among others, reduced
maximal aerobic capacity (peak oxygen consumption), reduced ventilatory equivalent for carbon dioxide, and
reduced end-tidal carbon dioxide pressure. fConsider CPET in the diagnostic work-up.
https://doi.org/10.1183/13993003.01647-2019 49
ACUTE PULMONARY EMBOLISM | S.V. KONSTANTINIDES ET AL.
nurse-led care models to deliver follow-up have been shown to be effective after acute coronary syndrome
[473], in primary care-based management of chronic diseases [474], and in community based
self-management initiatives [475]. A recently published study investigated the care of 42 patients followed
at a pulmonary arterial hypertension (PAH)/CTEPH nurse-led outpatient clinic and showed positive
results [476]. During patient follow-up visits, appropriately qualified nurses screen for signs and symptoms
indicating VTE recurrence or complications of treatment, and assess adherence to medication. Nurses
work collaboratively with patients using behavioural frameworks and motivational interviewing, to identify
and modify associated risk factors (smoking cessation, diet, physical activity, and exercise). In addition,
they promote self-management skills such as the use of compression stockings, safe increase in mobility,
increased awareness of signs of recurrence, or complications.
10.4. Recommendations for follow-up after acute pulmonary embolism
Recommendations Classa Levelb
Routine clinical evaluationc of patients 3–6 months after the acute PE episode is 
recommended [288, 352, 353, 437].
BI
An integrated model of patient care after PE (involving hospital specialists, appropriately 
qualified nurses, and primary care physicians) is recommended to ensure optimal transition 
from hospital to community care.
CI
In symptomatic patients with mismatched perfusion defects persisting on V/Q scand beyond 
3 months after acute PE, referral to a PH/CTEPH expert centre is recommended, after 
taking into account the results of echocardiography, natriuretic peptide levels, and/or
CPET [477].
CI
Further diagnostic evaluatione should be considered in patients with persistent or 
new-onset dyspnoea/exercise limitation after PE.
CIIa
Further diagnostic evaluatione may be considered in asymptomatic patients with risk factors 
for CTEPHf [447–449, 478].
CIIb
CPET: cardiopulmonary exercise testing; CT: computed tomography; CTEPH: chronic thromboembolic
pulmonary hypertension; PE: pulmonary embolism; PH: pulmonary hypertension; V/Q: ventilation/perfusion
(lung scintigraphy). aClass of recommendation. bLevel of evidence. cFor symptoms suggesting recurrence,
bleeding, malignancy, or persistent or new-onset exercise limitation, and to decide on extension of
anticoagulant treatment. dAlternatively, dual-energy CT may be used, if appropriate expertise and
resources are available on-site. eAs proposed in the algorithm shown in figure 8. fRisk factors and
predisposing conditions for CTEPH are listed in table 13.
11. Non-thrombotic pulmonary embolism
This section is included in the supplementary data.
12. Key messages
The ESC Task Force has selected 10 simple key messages and rules to guide physicians in the diagnosis
and management of PE:
1) In patients presenting with haemodynamic instability, perform bedside TTE as a fast, immediate
step to differentiate suspected high-risk PE from other acute life-threatening situations.
2) If you suspect acute PE, institute anticoagulation therapy as soon as possible, while the diagnostic
workup is ongoing, unless the patient is bleeding or has absolute contraindications to this therapy.
3) Use recommended, validated diagnostic algorithms for PE, including standardized assessment of
(pre-test) clinical probability and D-dimer testing. They help to avoid unnecessary, expensive, and
potentially harmful imaging tests and exposure to ionizing radiation.
4) If the CTPA report suggests single subsegmental PE, consider the possibility of a false-positive
finding. Discuss the findings again with the radiologist and/or seek a second opinion to avoid
misdiagnosis, and unnecessary, potentially harmful anticoagulation treatment.
5) Confirmation of PE in a patient, without haemodynamic instability, must be followed by further
risk assessment involving clinical findings, evaluation of the size and/or function of the RV,
and laboratory biomarkers as appropriate. This information will help you to decide on the
need for reperfusion treatment or monitoring for patients at elevated risk, or consider the
option of early discharge and continuation of anticoagulation on an ambulatory basis for patients at
low risk.
6) As soon as you diagnose (or strongly suspect) high-risk PE, select the best reperfusion option
(systemic thrombolysis, surgical embolectomy, or catheter-directed treatment) considering the
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patient’s risk profile, and the resources and expertise available at your hospital. For patients with
intermediate−high-risk PE, reperfusion is not first-line treatment, but you should prospectively plan
the management strategy with your team to have a contingency plan ready if the situation
deteriorates.
7) Prefer anticoagulation with a NOAC over the “traditional” LMWH−VKA regimen unless the patient
has contraindication(s) to this type of drug.
8) Always remember that, with the exception of acute PE provoked by a strong transient/reversible risk
factor, there is a lifelong risk of VTE recurrence after a first episode of PE. Consequently, re-examine
the patient after the first 3− 6 months of anticoagulation, weigh the benefits versus risks of
continuing treatment, and decide on the extension and dose of anticoagulant therapy, also
considering the patient’s preference. Remember to recommend regular follow-up examinations, e.g.
at yearly intervals.
9) If you suspect PE in a pregnant patient, consider diagnostic pathways and algorithms including
CTPA or V/Q lung scan, which can be used safely during pregnancy.
10) After acute PE, patients should not be lost to follow-up. Apart from checking for possible signs of
VTE recurrence, cancer, or bleeding complications of anticoagulation, ask the patient if there is
persisting or new-onset dyspnoea or functional limitation. If yes, implement a staged diagnostic
workup to exclude CTEPH or chronic thromboembolic disease, and to detect/treat comorbidity or
“simple” deconditioning. Follow-up imaging is not routinely recommended in an asymptomatic
patient, but it may be considered in patients with risk factors for development of CTEPH.
13. Gaps in the evidence
13.1. Diagnosis
• The optimal method to adjust (based on the patient’s age or in combination with clinical probability)
the D-dimer threshold, permitting the exclusion of PE while reducing the number of unnecessary
imaging tests to a minimum, remains to be determined.
• The diagnostic value and clinical significance of isolated subsegmental contrast-filling defects in the
modern CTPA era remain controversial.
• No robust data exist to guide the decision on whether to treat incidental PE with anticoagulants
compared with a strategy of watchful waiting.
• For patients presenting with non-traumatic chest pain, the benefits versus risks of “triple rule-out” (for
coronary artery disease, PE, and aortic dissection) CT angiography need further evaluation before such
an approach can be routinely recommended.
13.2. Assessment of pulmonary embolism severity and the risk of early death
• The optimal, clinically most relevant combination (and cut-off levels) of clinical and biochemical
predictors of early PE-related death remain to be determined, particularly with regard to identifying
possible candidates for reperfusion treatment among patients with intermediate-risk PE.
• The need for assessment of the RV status in addition to clinical parameters, to classify a patient with
acute symptomatic PE as being at low versus intermediate risk, needs to be confirmed by further
prospective management (cohort) studies.
13.3. Treatment in the acute phase
• The clinical benefits versus risks of reduced-dose thrombolysis and catheter-based reperfusion
modalities in patients with intermediate–high-risk PE should be evaluated in prospective randomized
trials.
• The place of ECMO in the management of acute high-risk PE awaits support by additional evidence
from prospective management (cohort) studies.
• The optimal anticoagulant drug(s) and regimen in patients with renal insufficiency and CrCl
<30 mL/min remain unclear.
• The criteria for selecting patients for early discharge and outpatient treatment of PE, and particularly
the need for assessment of the RV status with imaging methods and/or laboratory markers in addition
to calculating a clinical score, need to be further validated in prospective cohort studies.
13.4. Chronic treatment and prevention of recurrence
• The clinical value and the possible therapeutic implications of models or scores assessing the risk of
VTE recurrence, and the risk of bleeding under anticoagulation, need to be revisited in the NOAC era.
• The effectiveness of extended treatment with a reduced dose, or apixaban or rivaroxaban, should be
confirmed in patients with a high risk of recurrent PE.
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• The evidence supporting the efficacy and safety of NOACs for the treatment of PE in patients with
cancer needs to be extended by further studies.
• In patients with cancer, the anticoagulant regimen and dose after the first 6 months should be clarified
and prospectively tested.
• The optimal time for discontinuing anticoagulant treatment after an episode of acute PE in patients
with cancer is yet to be determined.
13.5. Pulmonary embolism and pregnancy
• Diagnostic algorithms for PE in pregnancy, using modern radiological imaging techniques and low
radiation doses, need to be prospectively tested in adequately powered cohort studies.
• Controversy persists on the optimal LMWH dose and regimen for the treatment of PE during
pregnancy.
• NOACs are not allowed in pregnancy. However, if exposure to these drugs occurs during pregnancy
despite this warning, any possible effects on the fetus should be recorded to provide more precise
information on the risks and complications of these drugs, and adapt the instructions to physicians in
the future.
13.6. Long-term sequelae of pulmonary embolism
• The optimal follow-up strategy, including the spectrum of diagnostic tests that may be necessary, in
patients with persisting symptoms and functional limitation after acute PE needs to be defined and
prospectively validated.
• In the absence of persisting symptoms or functional limitation after acute PE, the criteria for
identifying patients whose risk of developing CTEPH may be sufficiently high to justify further
diagnostic workup require further elaboration and validation in prospective cohort studies.
14. “What to do” and “what not to do” messages from the Guidelines
Diagnosis Classa
In suspected high-risk PE, perform bedside echocardiography or emergency CTPA (depending on 
availability and clinical circumstances) for diagnosis.
I
Risk assessment 
Stratify patients with suspected or confirmed PE, based on the presence of haemodynamic 
instability, to identify those at high risk of early mortality.
I
In patients without haemodynamic instability, further stratify PE into intermediate- and low-risk 
categories.
I
In suspected high-risk PE, initiate intravenous anticoagulation with UFH without delay, including a 
weight-adjusted bolus injection.
I
In suspected PE without haemodynamic instability, use validated diagnostic criteria. I
In suspected PE without haemodynamic instability, initiate anticoagulation in case of high or 
intermediate clinical probability, while diagnostic workup is in progress.
I
Base the diagnostic strategy on clinical probability, using either clinical judgement or a validated 
prediction rule.
I
Measure D-dimers in plasma, preferably with a highly sensitive assay, in outpatients/emergency 
department patients with low or intermediate clinical probability, or who are PE-unlikely.
I
Reject the diagnosis of PE (without further testing) if CTPA is normal in a patient with low or 
intermediate clinical probability, or if the patient is PE-unlikely.
I
Reject the diagnosis of PE (without further testing) if the perfusion lung scan is normal. I
Accept the diagnosis of PE if CTPA shows a segmental or more proximal filling defect in a patient 
with intermediate or high clinical probability.
I
Accept the diagnosis of VTE if CUS shows a proximal DVT in a patient with clinical suspicion of PE. I
Do not measure D-dimers in patients with high clinical probability, as a normal result does not 
safely exclude PE.
III
Do not perform CT venography as an adjunct to CTPA. III
Do not perform MRA to rule out PE. III
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CT: computed tomography; CTPA: computed tomographic pulmonary angiography/angiogram; CTEPH:
chronic thromboembolic pulmonary hypertension; CUS: compression ultrasonography; DVT: deep vein
thrombosis; INR: international normalized ratio; LMWH: low-molecular weight heparin; MRA: magnetic
resonance angiography; NOAC(s): non-vitamin K antagonist oral anticoagulant(s); PE: pulmonary
embolism; UFH: unfractionated heparin; VKA: vitamin K antagonist; V/Q: ventilation/perfusion (lung
scintigraphy); VTE: venous thromboembolism. aClass of recommendation.
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Treatment in the acute phase 
Administer systemic thrombolytic therapy to patients with high-risk PE. I
Chronic treatment and prevention of recurrence 
Administer therapeutic anticoagulation for ≥3 months to all patients with PE. I
PE in pregnancy 
Perform formal diagnostic assessment with validated methods if PE is suspected during pregnancy 
or in the post-partum period. I
Administer therapeutic, fixed doses of LMWH, based on early pregnancy weight, in the majority of 
pregnant women without haemodynamic instability. I
Do not insert a spinal or epidural needle within 24 h since the last LMWH dose. III
Do not administer LMWH within 4 h of removal of an epidural catheter. III
Do not use NOACs during pregnancy or lactation. III
Discontinue therapeutic oral anticoagulation after 3 months in patients with first PE secondary to a 
major transient/reversible risk factor.
I
Continue oral anticoagulant treatment indefinitely in patients presenting with recurrent VTE (at 
least one previous episode of PE or DVT) that is not related to a major transient or reversible risk 
factor.
I
Continue oral anticoagulant treatment with a VKA indefinitely in patients with antiphospholipid 
antibody syndrome.
I
In patients who receive extended anticoagulation, reassess drug tolerance and adherence, hepatic 
and renal function, and the bleeding risk at regular intervals.
Post-PE care and long-term sequelae 
Routinely re-evaluate patients 3–6 months after acute PE. I
Implement an integrated model of care after acute PE, in order to ensure optimal transition from 
hospital to ambulatory care.
I
Refer symptomatic patients with mismatched perfusion defects on V/Q lung scan beyond 3 months 
after acute PE to a pulmonary hypertension/CTEPH expert centre, taking into account the results of 
echocardiography, natriuretic peptide, and/or cardiopulmonary exercise testing.
I
I
Surgical pulmonary embolectomy for patients with high-risk PE, in whom recommended 
thrombolysis is contraindicated or has failed.
I
If anticoagulation is initiated parenterally in a patient without haemodynamic instability, prefer 
LMWH or fondaparinux over UFH.
I
When oral anticoagulation is initiated in a patient with PE who is eligible for a NOAC (apixaban, 
dabigatran, edoxaban, or rivaroxaban), prefer a NOAC.
I
As an alternative to a NOAC, administer a VKA, overlapping with parenteral anticoagulation until an 
INR of 2.5 (range 2.0–3.0) has been reached.
I
Administer rescue thrombolytic therapy to a patient with haemodynamic deterioration on 
anticoagulation treatment.
I
Do not use NOACs in patients with severe renal impairment or in those with antiphospholipid 
antibody syndrome.
III
Do not routinely administer systemic thrombolysis as primary treatment in patients with 
intermediate- or low-risk PE.
III
Do not routinely use inferior vena cava filters. III
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